CA2212645A1 - Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection - Google Patents

Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Info

Publication number
CA2212645A1
CA2212645A1 CA002212645A CA2212645A CA2212645A1 CA 2212645 A1 CA2212645 A1 CA 2212645A1 CA 002212645 A CA002212645 A CA 002212645A CA 2212645 A CA2212645 A CA 2212645A CA 2212645 A1 CA2212645 A1 CA 2212645A1
Authority
CA
Canada
Prior art keywords
domain
binding affinity
human
binds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002212645A
Other languages
French (fr)
Inventor
Damien John Dunnington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2212645A1 publication Critical patent/CA2212645A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invented is a method of treating autoimmune diseases in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.

Description

CA 0221264~ 1997-08-08 AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION

BACKGROUND OF THE INVENTION
~ S The src-related, lymphocyte-specific protein tyrosine kinase, pS6'C''(lck), is physically associated through its unique amino-termin~l domain with the cytoplasmic tail of CD4 in T lymphocytes. The CD4 associated lck is an essentialcomponent in the T cell activation c~cc~de, and an intact lck SH2 dom~in/CD4 complex is required for functional immnn~ response of T cells to antigen. Inhibition of the lck SH2 domain/CD4 complex results in T cell-specific immunosuppression.
A number of polypeptide growth factors and hormones m~.tli~te their cellular effects through a signal tr~nc~luction pa~llw~y. Transduction of signals from the cell surface receptors for these ligands to intracellular effectors frequently involves phosphorylation or dephosphorylation of specific protein substrates by regulatory protein tyrosine kinases (PTK) and phosphatases. Tyrosine phosphorylation may bethe primary, or possibly even the sole, indicator of signal transduction in multicellular organisms. Receptor-bound and intracellular PTKs regulate cell proliferation, cell dirr~,re;llLiation and ci~n~lling processes in immnne system cells.
Aberrant protein tyrosine kinase activity has been implicated or is sllcpecte-l in a number of pathologies such as diabetes, atherosclerosis, psoriases, septic shock, bone loss, anemia, many cancers and other proliferative diseases. Accordingly, tyrosine kinases and the signal transduction pathways which they are part of arepotential targets for drug design. For a review, see Levitzki et al. in Science 267, 1782-1788 (1995).
Many of the proteins comprising signal tr~nsduction pathways are present at low levels and often have opposing activities. The properties of these sign~lling molecules allow the cell to control transduction by means of the subcellular location and juxtaposition of effectors as well as by balancing activation with repression such that a small change in one pathway can achieve a switching effect.
The formation of tr~n~-lucing complexes by juxtaposition of the signalling molecules through protein-protein interactions are m~ tt-d by specific docking domain sequence motifs. Src homology 2 (SH2) domains, which are conserved non---I---CA 0221264~ 1997-08-08 catalytic sequences of approximately 100 amino acids found in a variety of .cign~lling molecules such as non-receptor PTKs and kinase target effector molecules and in oncogenic proteins, play a critical role. The SH2~1Qm~in~ are highly specific for short phosphotyrosine-cont~ining peptide sequences found in 5 autophosphorylated PTK receptors or intracellular tyrosine kin~ces Approximately 60 proteins having distinct catalytic or other functional c~om~in~ yet sharing conserved SH2 domains, conserved sequences of approximately100 amino acids, have been ic~Pntified. It is not known precisely which physiological responses in the body are controlled by each of these SH2 domains.10 Further, the SH2 domain-ligand/compound interactions are highly specific such that minor modifications in the structure of the ligand/compound will significantly alter the selectivity with which the ligand/compound binds to the various SH2 domains.The consequences of non selective antagonism of SH2 domains can be quite severe. For example, the src SH2 dom~in, the lck SH2 domain and the fyn SH2 15 domain are structurally similar, possessing a high degree of conservation between the ~lom~in~ Antagonism of the src SH2 domain is indicated as effecting bone resorption while antagonism of the lck SH2 domain (discussed herein) or the fyn SH2 domain induces immuno~u~lc:,sion. The inhibition of bone resorption would be undesirable in long term therapy which requires the induction of 20 immuno~u~plcs~ion.
Furthermore, it would be impractical to assay potential lck SH2 domain antagonists in binding studies against all 60 known SH2~iom~in~ Presently, thereare no known compounds which selectively interact with the lck SH2-1om~in It would be desirable to provide methods and compounds which allow the treatment of ~uLoi"-"llm~ diseases and allograft rejection by antagonizing the lck SH2 domain but which avoid the production of side effects observed in non-selective SH2 domain antagonists.
As disclosed herein it has unexpectedly been discovered that selective lck SH2 domain antagonists can be identified by binding assays against the subset ofSH2 domains consisting of; the src SH2 domain, the lck SH2 domain, the fyn SH2 CA 0221264~ 1997-08-08 domain, the ~ 2 SH2 domain, the p85 domain, the Grb2 SH2 domain and the hcp SH2 domain.
From the binding information described hereinafter, it has unexpectedly been discovered that compounds which are specific for a human lck SH2 domain with a 5 binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 dom~in, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the co.1.~ou1.d l0 binds to such lck SH2 domain are effective for treating aulo;~ -e diseases and allograft rejection.

SUMMARY OF THE INVENTION
The present invention provides a method of treating autoimmllne diseases in 15 a subject which comprises ~Amini.~tering to the subject a the.,.pe~.lic~lly effective amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which thecompound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 domain, a human Grb2 domain, a human SH-PTP2 SH2 20 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.
The present invention also provides a method of inhibiting allograft rejection in a subject which comprises ~rlmini~tering to the subject an allograft rejection 25 inhibiting amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 domain, a human Grb2 domain, a human SH-PTP2 ~ SH2 domain and a human p85 SH2 domain with a binding affinity which is greater 30 than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.

CA 0221264~ 1997-08-08 The present invention also provides a method of inducing immunosuppression in a subject which comprises ~(1mini.ctering to the subject animmuno~u~plcssion inducing amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 domain, a human Grb2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "~lltoi,.~ . diseases" means any disorder char~ct.ori7ecl by an overly active imml-ne response or an immllnr. response wrongly directed against self antigen. The ~iGr~lc;d ~ltnimm1lne disease is rh~l-m~toid arthritis. Other diseases such as mllltiple sclerosis, systemic lupus erythematosis and type I diabetes are also inrl~
As used herein, the term "treating" and derivatives thereof means prophylactic or thel~eulic therapy.
As used herein, the term "compound" means a nonpeptide chrmir~l compound.
As used herein, unless other wise defined, the term "lck SH2 domain antagonists" means a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher, preferably greater than one hundred-fold higher, than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 domain, a human Grb2 SH2, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower, preferably greater than one hundred-fold lower, than the binding affinity with which the compound binds to such lck SH2 ~lom~in The present invention provides a method of treating autoimmune diseases in a subject which comprises ~mini~tering to the subject a therapeutically effective CA 0221264~ 1997 - 08 - 08 WO 96l24343 PCT/US96/01964 amount of a eompound whieh (a) binds to a human lek SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with whieh theeol.lpoulld binds to a human sre SH2 domain and a human fyn SH2 domain, and (b) binds to a human hep SH2 tiom~in, a human Grb2 SH2, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity whieh is greater than fifty-fold lower than the binding affinity with whieh the eompound binds to sueh lek SH2 domain.
A plcfcllcd aspeet of the invention provides a method of treating autoimmlln~ diseases in a subjeet whieh eomprises ~iminicte.ring to the subjeet a therapeutieally effeetive amount of a eompound whieh (a) binds to a human lek SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with whieh the eompound binds to a human sre SH2 domain and a human fyn SH2 domain.
A preferred aspeet of the invention provides a method of treating au~oi.~ e diseases in a subjeet whieh eomprises ~flmini.ctering to the subjeet athcl~culieally effeetive amount of a eompound whieh (a) binds to a human lek SH2domain with a binding affinity greater than one hundred-fold higher than the binding affinity with whieh the eolll~oulld binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hep SH2 domain, a human Grb2 SH2, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity whieh is greater than one hundred-fold lower than the binding affinity with which the eompound binds to sueh lek SH2 domain.
A ~lcrcllcd aspect of the invention provides a method of treating autoimm-m~ ce~ces in a subject which comprises ~flmini.ctt~ring to the subject athel~eulically effeetive amount of a compound which (a) binds to a human lck SH2domain with a binding affinity greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
The invention also provides a method of inhibiting allograft rejection in a subject which eomprises ~rlmini.ctering to the subject an allograft rejection inhibiting amount of a compound which (a) binds to a human lck SH2 domain with a binding CA 0221264~ 1997-08-08 affinity greater than fifty-fold higher, ~lcfeldbly greater than one hundred-fold higher, than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 domain, a human Grb2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower, preferably greater than one hundred-fold lower, than the binding affinity with which the compound binds to such lck SH2 domain.
A ~lcfe~lcd aspect of the invention provides a method of inhibiting allograft rejection in a subject which comprises ~fiminictering to the subject an allograft rejection inhibiting amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher, preferably greater than one hundred-fold higher, than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
The invention also provides a method of inducing immunosuppression in a subject which comprises ~lminictering to the subject an immunosuppression inducing amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher, preferably greater than one hundred-fold higher, than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain, and (b) binds to a human hcp SH2 ~ m~in, a human Grb2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower, preferably greater than one hundred-fold lower, than the binding affinity with which the compound binds to such lck SH2 domain.
A p,efel,cd aspect of the invention provides a method of inducing immunosuppression in a subject which comrri.ces arlminictering to the subject animmunosuppression inducing amount of a compound which (a) binds to a human lck SH2 domain with a binding affinity greater than fifty-fold higher, preferably greater than one hundred-fold higher, than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.

CA 0221264~ 1997-08-08 The inhibitory activity of compounds at the different human SH2 domains was determin~cl in vitro using SH2 domains expressed as fusion proteins in E. coli as further described in detail in Example 11 below.
The data shown in the accompanying Tables 1 and 2 inrlic~te the ability of 5 the stated compounds to antagonize lck SH2 domain. Compounds indicated as selective lck SH2 domain antagonist from the assays in Example 11 are tested in known assays for their ability to induce immunosuppressive activity. Preferred assays include:
1) The IL2 Production Assay - which measures the production of IL2 in T
10 cells in response to various stimuli. The most commonly used T cell is the Jurkat human T cell line. The Jurkat is stim~ te~l with, a) mitogenic lectin (phytohem~glutinin or PHA) plus calcium inonophore or plus phorbol esters, or b) T
cell receptor antibody plus phorbol esters. The mea~ulGlllent of IL2 by ELISA
specific for human IL2 inclic~tt-s the level of activity and 2) The Three wav Human Mixed Lymphocvtes Reaction (MLR) - which mimics of response to foreign antigen. This assay measures the response of lymphocytes from one individual to the foreign antigens present in blood cells of another individual. The lymphocytes from the blood of three different donors (3-way response) are mixed together and in~ ub~te~l in complete growth medium for 4 -20 5 days. The ~letermin~tion cell prolirtlalive response by mP~cllring thymidine incorporation in~ t~s the level of activity.
Activity in these assays is recognized in the art as correlating with efficacy in treating autoimm~lnto diseases in vivo. Activity in these assays is also recognized in the art as correlating with efficacy in inhibiting allograft rejection in vivo. Activity 25 in these assays is also recognized in the art as correlating with efficacy in inducing immunosuppression in vivo.
The present invention therefore provides a method of inducing imrnunosuppression, which comprises ~iminictering a quantity of a lck SH2 domainantagonists defined as herein in a quantity effective to induce im~nunosuppression.
30 The drug may be ~iminictered to a patient in need of immunosuppression by anyconventional route of ~riminictration~ including, but not limited to, intravenous, CA 0221264~ 1997-08-08 intr~mllccul~r, oral, subcutaneous, intr~lerm~l, and ~alGntGl~l. The quantity effective to induce immunosuppression is from about 0.001 mg per kg to about 10.0 mg per kg of subject body weight. The selected dose will be an efficacious, nontoxic quantity selected from about 0.001 mg per kg to about 10.0 mg per kg of5 subject body weight. The sçlPcted dose will be ~-lminictered from about 1-6 times daily.
The method of in-lucing immllno~up~lGssion disclosed in the present invention may also be carried out using a ph~rm~reutir~l composition comprising an lck SH2 domain antagonists defined herein and a ph~rm~reutically acceptable carrier. The composition may contain between 0.05 mg and 500 mg of a lck SH2 domain antagonist, and may be conctitllt~rl into any form suitable for the mode of minictration selected. Compositions suitable for oral ~ciminictration include solid forms, such as pills, c~rsulec, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixers, and ~ls~ell:,ions. Forms useful for parenteral ~(1minictration include sterile solutions, emulsions, and suspensions.
The present invention further provides a method of inhibiting allograft rejection, which compri.ces ~riminictering a quantity of a lck SH2 domain antagonists defined as herein in a quantity effective to inhibit allograft rejection. The drug may be ~iminictrred to a patient with a recently impl~nted allograft or in anticipation of receiving an allograft by any conventional route of s/~lrninictration, including, but not limited to, intravenous, int ~ sc~ r, oral, subcutaneous, intradermal, and parenteral. The quantity effective to inhibit allograft rejection is from about 0.001 mg per kg to about 10.0 mg per kg of subject body weight. The selected dose will be an efficacious, nontoxic quantity selected from about 0.001 mg per kg to about 10.0 mg per kg of subject body weight. The selected dose will be ~Aminictered from about 1-6 times daily.
The method of inhibiting allograft rejection disclosed in the present invention may also be carried out using a ph~rrn~reutical composition comprising an lck SH2 domain antagonists defined herein and a ph~rm~reutically acceptable carrier. Thecomposition may contain between 0.05 mg and 500 mg of a lck SH2 domain antagonist, and may be constituted into any form suitable for the mode of CA 0221264~ 1997-08-08 ~Aminictration se.lectecl Compositions suitable for oral ~Aminictration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixers, and suspensions. Forms useful for parenteral aAminictration include sterile solutions, emulsions, and suspensions.
S The drug may otherwise be ~lc;p~,d as a sterile solid composition whichmay be dissolved or sncpçn~le~l at the time of ~Aminictration using sterile water, saline, or other a~p.~,pliate sterile injectable mP.Aillm Carriers are intPnAe~l to include nP.cessa~ and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes and coatings.
Optimal dosages to be ~Aminictered may be readily determined by those skilled in the art, and will vary with the particular lck SH2 domain antagonist in use, the strength of the plGp~alion, the mode of ~Aminictration~ and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of ~Aminictration.
The invention also provides for the use of a lck SH2 domain antagonists in the m~nnfartllre of a m~AicamP.nt for use in the treatmP.nt of autoi,-,-"ll,-ç tliceace The invention also provides for the use of a lck SH2 domain antagonists in the manufacture of a mP.Aic~mPnt for use in inhibiting allograft rejection.
The invention also provides for the use of a lck SH2 domain antagonists in the m~nllfactllre of a mPAir~mPnt for use in in-lucing immunosuppression.
The invention also provides for a ph~rm~reutic~l composition for use in the treatment of autoimmnn~. diseases which comprises a lck SH2 domain antagonists.
The invention also provides for a pharm~re-ltic~l composition for use in inhibiting allograft rejection which comprises a lck SH2 domain antagonists.
The invention also provides for a pharmareutir~l composition for use in inducing immunosuppression which comprises a lck SH2 domain antagonists.
No unacceptable toxicological effects are expected when the methods of the invention are utilized in accordance with the present invention.
Without further elaboration, it is believed that one skilled in the art can, using the preceAing description, utilize the present invention to its fullest extent.

g CA 0221264~ 1997-08-08 The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

Experimental Details As used herein, unless otherwise intlic~t~l, the symbol ~ means ~C.
L-3,5-Dibromotyrosine can be prepared by rnethods known in the art, for ex~mple as described in "Thyoid Hormones and Analogues. I. Synthesis, Physical Plu~c~Lies and Theoretical Calculations" E. C. Jorgensen, H~rmnn~l Proteins and Peptides, Vol. VI, 1978, Academic Press, N.Y. and references cited therein.
L-3,5-dibromo-N-trifluoroacetyl-tyrosine methyl ester (for use in Example 2 (e) and in Example 2B (b)) can be prepared according to the following procedure.L-3,5-Dibromotyrosine (500 g) was suspended in methanol (5 liters) and dry hydrogen chloride passed through the stirred suspension for 5 hours. The reaction l-u~lu~c was ~va~oldt~d to dryness, the residue suspended in water (4 liters), and the pH adjusted to 6 with 40% sodium hydroxide. The precipitate was collected and washed with water to give L-3,5-dibromotyrosine methyl ester (467 g, 90%), m.p.
201~-203~. The ester (768 g) was suspended in chlo,~,fc"", (2.7 liters) and ethyl acetate (2.7 liters), then trifluoroacetic anhydride (565 g) was added over 0.5 hour, keeping the tCllll cldlule below 35~. The mixture was left overnight, then water (2 liters) was added and the pH adjusted to 7 by the addition of saturated sodium bicarbonate solution. The organic layer was removed, washed with water, dried with anhydrous m~gnt~cillm sulphate and ~va~uldt~d. The residue was recryst~ ed from aqueous methanol to give L-3,5-dibromo-N-trifluoroacetyl-tyrosine methyl ester (786 g, 81%), m.p. 136~-7~.

Scheme 1 as used in Example 6 below ~C02H ~CO2 Kaiser oxime resin CONHR"
RHN~- ~ RHN~ --~ R'COHN~
1: R=H 3: R=Boc 2: R=Boc 4: R=H 6 5: R=COR' CA 0221264~ 1997-08-08 The amino group of 4-tran~-aminomethyl-cyclohexyl-carboxylic acid 1 is protected with a standard protective group such as with a Boc group (Boc anhydride, NaOH, H2O, dioxane) to form 2, then is coupled to Kaiser oxime resin (Kaiser, E.T.;
et al JAm Chem Soc 1985, 107, 7087-7092) using a coupllng reagent such as DCC
5 to form 3. The amine is then deprotected under standard conditions (25% TFA, methylene chloride) to form 4, then is acylated with standard conditions (such as with HBTU, NMM in DMF or DCC or DIC in DMF or NMP) to form 5. The compound is then cleaved from the resin with various amines to form the final desired product 6.
Colllpoullds 1 to 10 are prepared according ~o Fl~mpl~s 1 to 10 which follow.
Example 1 Preparation of 7-rD.L-a-Amino-a-(4-carboxyphenyl)acetamidol-3-r2-(5-methyl-1~3.4-thi~ 7l 1yl)thiomethyll~-cephem-4-carboxylic Acid (Compound 1) HO~o~N;~S~,~S

a) 4-Hydroxymethylb~-n7~1-1ehyde To a solution of 1,4-ben7tqnlo~1ie~rboxaldehyde (50.0 g, 0.373 mole) in dry tetrahydrofuran (200 mT ) under nitrogen in an ice bath was added dropwise lithium tri(tert-butoxy)~ minllm hydride (104.0 g, 0.410 mole) in 500 mL of tetrahydrofuran. After stirring for one half hour in an ice bath, the reaction mixture was poured into 2 L of ice cold 2 N hydrochloric acid. The aqueous solution was extracted with four 800 mL portions of ether. The combined ether layers were washed with sodium bicarbonate solution, brine and dried. Evaporation of the solvent afforded 46 g of crude material that was purified by chromatography (alumina, ether elution) to provide the title compound as a crystalline material (17.6 g, 35%): mp 44.5-46 ~C
b) 5-(4-Hydroxymethyphenyl)hydantoin CA 0221264~ 1997-08-08 To a stirred rnixture of 4-hydroxymethylber~7:lldehyde (10.0 g, 73.5 mmol) and ammonium carbonate (17.1 g, 150 mmol) in 110 rnL of 60% aqueous ethanol heated to 50 ~C there was added sodium cyanide (4.0 g, 81 mmol) in 10 mL of water. The llu~lult; was stirred and heated at 50-60 ~C for 3 h and then at 85 ~C for 5 one hour. After cooling in an ice bath, the pH of the solution was adjusted to 6 by addition of concentrated hydrochloric acid. Upon overnight cooling, the solid which had precipitated was filtered, washed with water and dried to provide the title compound (11.0 g, 72%): mp 189-196 ~C.
c) 4-Hydroxymethyphenylglycine A mixture of compound of Example l(b) (10.9 g, 53 mmol) and barium hydroxide octahydrate (25.5 g, 81 mmol) in 125 mL of water was stirred under reflux for 18 h. The reaction mixture was cooled and acidified to pH 1 with concentrated sulfuric acid; the barium sulfate was filtered and the pH of the filtrate brought to 6 with lead carbonate. After filtration of the lead sulfate, the filtrate was saturated with hydrogen sulfide and the lead sulfide filtered. The aqueous solution was then concentrated to 100 mL by ~eotroping with ethanol under reduced pl~S:iul~ to provide, after cooling, the title compound (5.2 g, 54%): mp 230-231 ~C.
d) N-tert-Butoxycarbonyl-4-hydroxymethyphenylglycine To a solution of 4-hydroxymethyphenylglycine (8.0 g, 44 mmol) and triethylamine (8.8 g, 87 mmol) in 160 mL of water was added tert-butoxycarbonyl azide (6.95 g, 49 mmol) in 120 mL of tetrahydrofuran. After stirring overnight at room t~ el~Lule, the reaction ll~ib~lule was washed twice with 200 mL potions ofether. The aqueous layer was covered with ether and acidified to pH 3-3.5 with 3 N
hydrochloric acid in an ice bath. The acidic solution was extracted with ether and the combined organic extrats washed with brine, dried and evaporated. The resulting oil was triturated with chloroform-hexane and the solid filtered off to provide the title compound (7.7 g, 63%): mp 139-141.5 ~C.
e) N-tert-Butoxycarbonyl-4-hydroxymethyphenylglycine Methyl Ester To a solution of compound of Example l(e) (5.6 g, 20 mmol) was added dimethyl sulfate (3.1 g, 24 mmol) and diisopropyl arnine (5.2 g, 40 mmol) in methanol (10 mL). The mixture was refluxed for 20 min and was then treated with 2 N aqueous hydrochloric acid. The aqueous solutin was extracted with ethyl acetate three times and the combined organic extracts washed with 5% aqueous sodium bicarbonate and brine. Evaporation of the solvent provided the title compound as an oil (3.2 g, 55%).
f) N-tert-Butoxycarbonyl-4-carboxyphenylglycine Methyl Ester CA 0221264~ 1997-08-08 A solution of the compourld of Exarnple l(e) (0.62 g, 2.1 mmol) in 50 ml of acetone was treated with excess Jones reagent (8N chromic acid) at 25~ C. The reaction mixture was stirred at room te~ .dtule for 2 hours. The green solid wasfiltered off and excess CrO3 was decomposed by isopropyl alcohol. The filtrate was 5 dried over anhydrous sodium sulfate and treated with activated charcoal. Solid was filtered off and the filtrate was eva~oldL~d to dryness to yield 0.38 g of titlecompound as white solid: mp 126-128 ~C.
g) l,l-Dimethylethyl N,N'-Bis(l-methylethyl)~ "i.,.i~l~te The title compound was prepared by reaction of neat N,N'-diisopropylcarbo-iiimi~lP (1.0 equiv) with 2-methyl-2-propanol (1.15 equiv~ in the presence of CuCl (0.01 equiv) for 1 day at room tenl~ldLulG, according to the procedure of Santini et al. ( J. Org. Chem. 1994, 59, 2261).
h) N-tert-Butoxycarbonyl-4-(tert-butoxycarbonyl)phenylglycine Methyl Ester A solution of the compound of Example l(f) (1.0 g, 3.2 mmol) and 1,1-dimethylethyl N,N'-bis(1-methylethyl)carb~mimifl~te (1.3 mg, 6.5 mmol) of in drydichlor~-m~oth~r~e was stirred at room telll~ dLulc over night. Di-isopropylurea was filtered off and the excess 1,1-dimethylethyl N,N'-bis(1-methylethyl)c~l ~ imicl~
was decomposed with water. Layers were separated and the dichloromethane 20 solution was washed with 5% aqueous sodium bicarbonate and brine and dried over anhydrous sodium sulfate. Solvent was evd~ldL~d off and the residue was treated with diethyl ether. Additional di-isopru~ylul~a was filtered off and the organicfiltrate was ev~pol~Lted to yield the title compound as an oil (870 mg, 74%).
i) N-tert-Butoxycarbonyl-4-(tert-buLo,~yc~l,..l,yl)phenylglycine A solution of the compound of Example l(h) (760 mg, 2.1 mmol) in 18 rnL
of 5% aqueous sodium bicarbonate, 18 rnL of 5% aqueous sodium carbonate and 36 mL of m.-th~nol was stirred ovenight at room temperature for 5 hours. The reaction mixture was diluted with water, washed with ethyl acetate and the aqueous solution was covered with fresh ethyl acetate and acidified to pH 2 with 3N HCl. Layers were separated and the aqueous solution was extraced with ethyl acetate 2 more times. Ethyl acetate solutions were dried over anhydrous sodium sulfate and evaporated to yield title compound as a white solid (600 mg, 82%): mp 77-79 ~C.
j) tert-Butyl 7-Amino-3-[2-(5-methyl-1,3,4-thi~ 7olyl)thiomethyl]~3-cephem~-carboxylate .
A solution of tert-butyl 7-aminocephalosporanate (prepared from 7-aminocephalosporanic acid by reaction with isobutylene and sulfuric acid in 1,2-dimethoxyethane, according to the procedure of Blacklock et al., J. Org. Chem.

CA 0221264~ 1997-08-08 1989, 54, 3907), sodium bicarbonate and 2-mercapto-5-methyl-1,3,4-thi~ 7ole in phosphate buffer (pH 6.4) is stirred for 6 h a~ 60 ~C. The reaction ~ lule is worked up by extraction with aqueous hydrochloric acidlethyl acetate to provide the title compound.
k) tert-Butyl 7-[D,L-a-(tert-Butoxycarbonylamino)-a-[4-(tert-butoxycarbonyl)phenyl]]~ et~mido-3-[2-(5-methyl-1,3,4-thi~ 37Olyl)thiomethyl]~3-cephem-4-carboxylate A mixture of N-tert-butoxycarbonyl4-(tert-butoxycarbonyl)phenylglycine of Example l(i) (351 mg, 1 mmol), tert-butyl 7-amino-3-[2-(5-methyl-1,3,4-thi~ 7olyl)thiomethyl]~3-cephem4-carboxylate of Example l(j) (368 mg, 1 mmol) and DCC (212 mg, 1 mmol) in dry dichloromtoth~nl~ was stirred at room te~ eldlù
for 3 hours. The dicyclohexylurea was filtered off and the filtrate was evaporated to dryness. The residue was dissolved in ethyl acetate and the ethyl acetate solution was washed with 5% aqueous sodium bicarbonate, 2.5% sulfuric acid, 5% aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. The solvent was evaporated to yield 0.6 g of crude product. pllrifi~tion by silica gel chromatography (elution with 30:70 ethyl acetate / ben_ene) provided the title compound (430 mg, 61%): mp 110-112 ~C.
1) 7-[D,L-a-Amino-a-(4-carb~ ~y~hel~yl)~- et~mido]-3-[2-(5-methyl-1,3,4-thi:~Ai~7O1yl)thiomethyl]~3-cephem4-carboxylic Acid A solution of the compound of Example l(k) (400 mg, 0.57 mmol) was stirred in 7.2 mL of trifluoroacetic acid and 0.8 mL of thiophenol. The reactionmixture was stirred at 0 ~C for 30 minntes and at room tt;lll~eldLulc for 1 hour. The solvents were evaporated off in a 40~ C water bath and the residue was lfiLul dl~d with diethyl ether three times; the solid product was dissolved in small amounts of methanol and the product was precipitated by addition of diethyl ether to afford the title compound (300 mg): mp 170-175 ~C.

Example 2 Preparation of L-3,5-Dibromo-3'-(6-oxo-3(1 H)-pyrida7inylmethyl)-thyronine (Compound 2) = ~
CA 0221264~ 1997-08-08 Br ~ ~ NH~
HO~ Br CO2H

N~N O
H

(a) o-Methoxyphenylacetonitrile (23.64 g) and 3,6-dichloropyridazine (23.93 g) were dissolved in dry dimethylform~mide (50 ml) and sodium hydride (16.23 g of a 50% dispersion in oil) was slowly added in portions to the stirred5 solution over 2 hours. The mixture was poured on to excess crushed ice and extracted with dichlolo...t~tl.~n~ The organic layer was removed and washed withwater, dried with anhydrous m~gn~ciurn sulphate, charcoaled and evaporated to dryness. The residue cryst~ ed from dichloromethane/petroleum spirit to give 1-(6-chloro-3-pyridazinyl)-1-(2-methoxyphenyl)-acetonitrile (35.5 g 85%), m.p. 91~-10 92~.
(b) This nitrile (33.5 g) was dissolved in concentrated hydrochloric acid (200 ml), acetic acid (100 ml) and water (100 ml) and the solution refluxed withstirring. After 6 hours the solvents were evaporated and the residue recrystallised from ethyl acetate/petroleum spirit to give 2-(6-oxo-3(1H)-pyridazinylmethyl)-anisole (21.4 g, 77%), m.p. 142~-3~.
(c) This pyridazinone (15.7 g) was dissolved in phosphorous oxychloride (22 ml) and the solution heated with stirring at 55~ (oil bath) for 1 hour. The cooled ll~i~Lul'e was slowly poured onto crushed ice, and extracted with dichloromethane.
The organic layer was separated and washed with saturated sodium bicarbonate solution, dried with anhydrous magnesium sulphate and evaporated. The residue was combined with a smaller batch (from 2.16 g of the pyridazinone) and extracted several times with boiling petroleum spirit (60~-80~). The combined extracts were charcoaled and evaporated to give 2-(6-chloro-3-pyridazinylmethyl)-anisole (16.95 g, 87%), m.p. 63~.
(d) To a stirred suspension of iodine tristrifluoroacetate (prepared by tre~tn-~nt of iodine (2.54 g) with fuming nitric acid (5 ml) in acetic anhydride and trifluoroacetic acid) in trifluoroacetic anhydride (25 ml) at -15~ was added the above chloropyridazine (9.39 g) in trifluoroacetic acid (20 ml) and trifluoroacetic anhydride (25 ml), keeping the telllpc,dLu~e below -15~. The mixture was stirred at CA 0221264~ 1997-08-08 room temperature overnight, concentrated, then a solution of sodium acetate (25 g) and sodium perchlorate (lS g) in water (200 ml) was added. The mixture was extracted with chloroform, the organic solution dried with anhydrous m~gnPcium sulphate, then concentrated to 50 ml and poured into stirred ether (250 ml). TheS precipitate was collected and dried to give crude 4,4'-dimethoxy-3,3'-bis-(6-chloro-3-pyridazinyl-methyl)-diphenyl iodonium perchlorate (14 g). lH NMR ~(DMSO-d6) 3.80 (3H, s,--OCH3), 4.20 (2H, s,~H2Ar), 7.05 (lH, m, Ar-SH), 7.65 (2H, m, PyH) and 8.00 (2H, m, Ar-2,6H).
(e) The above iodonium salt (12.45 g), L-3,5-dibromo-N-trifluoroacetyl tyrosine methyl ester (8.98 g), triethylamine (4.05 g) and copper bronze (1.0 g) were stirred in dichlor mPth~nP (50 ml) for 18 hours. The mixture was filtered, washed with aqueous acetic acid, 2N sodium hydroxide, then water, then dried with anhydrous m~gnecillm sulph~te and evaporated. The residue was combined with a smaller batch (from 0.72 g of the iodonium salt) and purified by column lS chromatography on silica gel (400 g). Elution with ethyl acetate/petroleum spirit (60~-80~) [1:3] gaveL-3,5-dibromo-3'-(6-chloro-3-pyridazinylmethyl)-O-methyl-N-trifluoroacetyl-1-thyronine methyl ester (4.0 g) as a tan coloured froth. lH NMR~(CDCl3) 3.06 (2H, m, ArCH2CH), 3.84 and 3.93(6H, 2s,--OCH3), 4.19(2H, s, ArCH2Py), 4.75(1H, m, ArCH2CH), 6.62(3H, m, ArH), 7.17(2H, m, PyH) and 7.23(2H, s, ArH).
(f) The above dibromo compound (3.27 g) was dissolved in acetic acid (20 ml) cont~ining sodium acetate (0.79 g). The solution was refluxed for 1.25 hours, sllfficient water (approximately 2 ml) added to dissolve the precipitatedsodium chloride, and the solution evaporated to dryness. The residue was partitioned between water and ethyl acetate, the organic layer removed and washed with saturated sodium bicarbonate, then dried with anhydrous m~gnPcium sulphate and evaporated to dryness. The residue was cryst~lliced from ethyl acetate/petroleum spirit (60~-80~) to give L-3,5-dibromo-O-methyl-3'-(6-oxo-3(1H)-pyridazinylmethyl)-N-trifluoro-acetylthyronine methyl ester (2.52 g, 79%), m.p. 176~-8~.
(g) This pyridazinone (2.45 g) was dissolved in dry dichlorom.oth~ne (40 ml) and cooled with stirring at 0~. Boron tribromide (6.46 g) in dichloromethane (3 ml) was added. A red-brown precipitate formed. The mixture was stirred at room temperature for l.S hours, then crushed ice was added. The mixture was filtered, the precipitate cnllçctecl and dissolved in 2N sodium hydroxide (30 ml). The solution was heated on a steam bath for 15 minlltPc, acetic acid was then added to pHS, and the mixture cooled. The resulting precipitate was collected, washed and dried to CA 0221264~ 1997-08-08 give L-3,5-dibromo-3'-(6-oxo-3(1H)-pyridazinylmethyl)-thyronine (1.74 g, 88%), m.p. 278~-9~ (dec.).
.Alt~rn~tively, instead of using the perchlorate salt prepared in (d) for reaction step (e), the iodonium trifluoro~-et~tt~ salt can be used which is plepal~,d as follows:
Iodine (159 g) was suspended in trifluoroacetic anhydride (1 liter) and stirred under nitrogen whilst fuming nitric acid (350 ml) was added over 1.5 hours, keeping the tc;~ eldLulc between 36~ and 40~. Trifluoroacetic anhydride (300 ml) was then added and the "li~Lùle m~int~in.-d at 40~ under a stream of nitrogen until all nitrogen oxides were removed, then allowed to stand at room lelll~ldlul~ ovçrnight The solvent was then removed under reduced ~l~S~ul~ and the residual solvent removedby azeotroping with trifluoroacetic anh~dride (2 X 300 ml). The pale yellow residual solid was then suspended in trifluoroacetic anhydride (1.2 liters) withstirring and was cooled to -20~. A solution of 2-(6-chloro-3-pyrida~h,yl",ethyl)anisole (600 g) in triflouoracetic acid ( 1.2 liters) was then added dropwise, m~ g the telll~ldLul~ between -10~ and -20~. The mixture was stirred at -10~ for 1 hour and at room tc~ )e,dLul~ ovçrnight then the solvent removed under reduced pressure and the residue poured into a solution of sodium sulphate (3.5 kg) in water (20 liters) with stirring. The pH of this llu~Lùle was adjusted to approximately pH 2 using dilute aqueous sodium hydroxide, then extracted with dichlorom~th~np (2 X 3 liters, 1 x 2 liters), the organic extracts co"lbined, dried (MgSO4), filtered, and reduced in volume to 2 liters, then added to vigorously stirred diethyl ether (12 liters). The dark grey precipitated solid was filtered off, washed with ether, and dried in a vacuum oven at 40~ for 6 hours to give 4,4'-~lim-othoxy-3,3'-bis-(6-chloro-3-pyridazinylmethyl) diphenyl iodonium trifluoroacetate (8.14 g, 90%), m.p. 145~-147~.
Further reaction of this salt using procedures analogous to those described in 2(e), (f) and (g) above gives the required L-3,5-dibromo-3'-(6-oxo-3(1H)-pyridazinyl-methyl)thyronine .

Example 2A
dtion of L-3 5-Dibromo-3'-(6-oxo-3( 1 H)-pyridazinylmethyl)thyronine (Compound 2) (a) 2-(6-Chloro-3-pyridazinylmethyl)anisole (prepared as described in Example 2(c)(2.35 g) was dissolved in dry dichloromethane (20 ml) and cooled with stirring to -50~. Boron tribromide (3 ml) was then added dropwise, and the solution was allowed to warm to room temperature. After 0.5 hours the orange reaction mixture was poured into ice/water (200 ml) and acetone added to dissolve the CA 0221264~ 1997-08-08 precipitated solid. The mixture was eYtr~- tt~A with dichloromPth~ne, the organic extracts were separated, washed with water, dried, and evaporated. The residue was recrystallised from ethyl acetate and petroleum spirit to give 2-(6-chloro-3-pyridazinylmethyl)-phenol (1.75 g, 80%), m.p. 132~-132.5~. Anal. Found: C, 59.61;
H, 4.13; N, 12.47; Cl, 16.09; C,lH9ClN2O Requires: C, 59.87; H, 4.11; N, 12.70; Cl, 16.07%.
(b) To a stirred solution of this phenol (2.4 g) and urea (14 g) in 75%
aqueous sulphuric acid (100 ml) t-butanol (17 ml) was added slowly. The mixture was stirred well and further quantities of t-butanol were added after 4 hours (18 ml), 24 hours (5 ml), and 28 hours (20 ml). After 120 hours the mixture was poured into water, the organic phase separated and discarded and the aqueous phase extractedthoroughly with ether. The combined ether extracts were washed with saturated brine, then dried and evd~ d~d. The residue was recryst~lliced from ether and petroleum spirit to give 2,4-di-t-butyl-6-(6-chloro-3-pyridazinylmethyl)phenol (3.43 g, 94%), m.p. 143.0~-143.5~. Anal. Found: C, 68.32; H, 7.51; N, 8.36; Cl, 10.89;C,9H25ClN2O. Requires: C, 68.56; H, 7.57; N, 8.41; Cl, 10.65%).
(c) A solution of this phenol (1.95 g), L-3,5-dibromo-N-trifluoroacetyl tyrosine methyl ester (3.24 g) in dietheyl ether (100 ml) was stirred under argon at room ~e~ ,ldtul~; and then treated with active m~ng7~n~se dioxide (3 X S g). After 4 hours the mixture was filtered, and ~ ,." tetrachloride (5 ml) added. After 2 minutes the dark solution was treated with water and extracted well with ethyl acetate. The organic extracts were combined, waslled with saturated brine, dried and evaporated. The residue was chromatographed on silica gel with petroleum spirit and ether as eluant to give L-3,5-dibromo-5'-t-butyl-3'-(6-chloro-3-pyridazinylmethyl)-N-trifluoroacetyl thyronine methyl ester (2.31 g, 55%), m.p.
84~-86~.
(d) A solution of this dibromothyronine (2.76 g) and anhydrous sodium acetate (0.78 g) in acetic acid (25 ml) was heated at reflux for 10 hours, then cooled and poured into ice-water. The precipitated solid was filtered off, dissolved in ethyl acetate, dried, and evaporated to give L-3,5-dibromo-5'-t-butyl-3'-(6-oxo-3(1H)-pyridazinylmethyl)-N-trifluoroacetylthyronine methyl ester, (2.4 g, 55%), m.p.
112~-115~.
(e) A solution of this pyridazinone (0.200 g) and Hbr (1 ml) in glacial acetic acid (20 ml) was heated at reflux for three days. The solution was then cooled, diluted with water, basified with aqueous 2N sodium hydroxide solution and brought to pH 6 by addition of acetic acid. The precipitated solid was filtered,washed, and dried to give L-3,5-dibromo-3'-(6-oxo-3(1H)-.

CA 0221264~ 1997-08-08 pyridazinylmethyl)thyronine (0.100 g, 65%), m.p. 245~-247~ (dec.), spectroscopically identical with that previously isolated (Example 2(g)).

Example 2B
Preparation of L-3.5-I:)ibromo-3'-(6-oxo-3(1H-pyridazinylmethyl)-thyronine (Compound 2) (a) To a solution of iodine fri~trifl~loroacetate (prepared by tre~tment of iodine (10.0 g) with fuming nitric acid (20.95 ml) in acetic anhydride and trifluoroacetic acid) in acetic anhydride (50 ml), cooled to -10~, was added dropwise a solution of 2-methoxybenzyl cyanide (30.0 g) in trifluoroacetic acid (60 ml) and acetic anhydride (30 ml). The te~ dlulG of the ll~x~Luie was m~int~in~-~l below 0~
during the addition then allowed to stand at room tem~e,dlule overnight. The mixture was then poured into a well-stirred ice-cold solution of sodium acetate (100 g) and sodium perchlorate (13.0 g) in water (600 ml). The solid which precipitated was filtered off, washed with water and diethyl ether to give 3,3'-dicyanomethyl-4,4i-dimethoxy-diphenyl iodonium perchlorate as a fine buff solid (23.6 g, 57%),m.p. 183~4~ (from methanol/diethyl ether).
(b) A solution of this iodonium salt (22.6 g), L-3,5-dibromo-N-trifluoroacetyl-tyrosine methyl ester, triethylamine (6.1 g) in dichlorom.oth~ne (300 ml) was treated with copper bron~ (1 g) and the ~ lulc stirred at room telll~eldture for 20 hours. The mixture was then filtered and the filtrate washed with 2N aqueous hydrochloric acid ( 2 X 200 ml), water (2 X 200 ml), and 2N aqueous sodium hydroxide solution (3 X 200 ml), then the organic solution was dried over m~gnt~sillm sulphate and evaporated under reduced pressure. The oily residue wasdissolved in dichlorometh~ne (30 ml) and poured into petroleum spirit. A solid precipitated which was filtered off and recryst~ e~l from dichlorom.oth~n~/petroleum spirit to give L-3,5-dibromo-3'-cyanomethyl-O-methyl-N-trifluoroacetylthyronine methyl ester as a colourless crystalline solid, m.p.
148~-149~. The mother liquors were chromatographed on silica gel to give furtherq~-~ntities of this compound (total = 8.05 g, 31%).
(c) To a solution of this dibromolhyl~ ille (120 mg) and 3,6-dichloropyridazine (31 mg) in dry dimethylf~-rm~mide (2 ml), sodium hydride (30 mg of a 50% suspension in oil) was added and the reaction mixture allowed to stand at room telll~eldLule for S0 min. It was then treated with ice, and the aqueous mixture extracted with dichloromPthzlne, the organic solution washed with saturated brine, then dried and evaporated. The residue was chromatographed on a preparative silica gel chromatography plate from which 3,5-dibromo-3'-(1-(6-chloro-3-CA 0221264~ 1997-08-08 pyridazinyl)-l-cyanomethyl)-O-mcthyl-N-trifluoroacetylLllyl~ ine methyl ester (5mg) was isolated. lH NMR ~(CDCl3) 3.12 (lH, m), 3.27 (lH, m), 3.79 (3H, s), 3.86(3H,s),4.86(1H,m),5.80(1H,s),6.72(1H,dd),6.83 (lH,d),7.04(1H,d),7.15 (lH, broad m), 7.37 (2H, s), 7.50 (2H, dd).
Elaboration of this interm~ t~ by standard methods gives the title compound.

Example 3 ~l cpal aLion of 8.8-Ethylenedioxy-2.3 ~7.8.9.10-hexahydro~-methyl- 1 H-benzorblthienor2.3-blpyrazolor3~4-dlpyridin-3-one (Co~ ou~d 3) H~ r CO~O

a) Ethyl 2-Cyano-2-(4,4,-ethylenedioxycyclohexylidene)acetate To a llli~Lulc of 1,4 cycloh.o.x~n~-linne monoethylene ketal (25 g, 0.160 mol) and ethyl cyanoacetate (18 g, 0.160 mol) in toluene (400 mL) was added dropwise diethylamine (25 g, 0.337 mol) at room telll~ dLulc. The reaction mixture was heated at reflux overnight (using a Dean Stark a~dLus). The ~lu~Lu~e was cooled and partitioned with ethyl acetate and saturated aqueous sodium bicarbonate (3x).
The organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo and ~cc~y~L;1lli7e~l from ethanol to yield the title compound as an white solid (15.8 g, 45%): mp 80-81 ~C; lH NMR (400 MHz, CDC13) ~ 4.28 (q, J = 7.2 Hz, 2 H), 4.00 (s,4H),3.18(t,J=6.5Hz,2H),2.85(t,J=6.5Hz,2H), 1.89(t,J=6.5Hz,2H), 1.82 (t, J= 6.5 Hz, 2 H), 1.35 (t, J= 7.1 Hz, 3 H).
b) Ethyl 2-Amino-6,6-ethylenedioxy-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate To a suspension of compound of F.x~mpl~ 3(a) (10 g, 45.6 mmol), sulfur (1.6 g, 50.2 mmol) in ethanol (164 mL) at 0 ~C, was added dropwise a solution of diethylamine (3.6 g, 50.2 mmol) in ethanol (26 mL). The resulting solution stirred at 0 ~C for 1 h, then at room temperature for 3.5 h. The reaction mixture was quenched with ethyl acetate and partitioned with saturated aqueous ammonium chloride solution. The aqueous phase was extracted with ethyl acetate, and the organic extracts were washed with brine. The combined organic extracts were dried over sodium sulfate, filtered, concentrated in vacuo and chromatographed (silica gel, CA 0221264~ 1997-08-08 gradient 5 to 10% CH2C12:EtOAc~ to yield the title compound as an oil (11.3 g, 87%). lH NMR (400 MHz, CDC13) o 4.25 (q, J = 7.1 Hz, 2 H), 4.02(s, 4 H), 2.92 (t, J=6.5Hz,2H),2.74(s,2H), 1.90(t,J=6.6Hz,2H), 1.33(t,J=7.1,3H).
c) Ethyl 7,7-Ethylenedioxy-4-hydroxy-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3--b]pyridine-2-carboxylate To a solution of compound of Example 3(b) (11.2 g, 39.5 mmol) in toluene (307 mL) at room te~ Glature was added ethyl 3-ethoxycrotonate (12.4 g, 78.6 mmol) and c~mphQrsulfonic acid (0.78 g, 3.4 rnmol). The reaction mixture was heated at reflux for 3.5 h using a Dean Stark trap. The llfi~lulè was then cooled, and to it was added dropwise a freshly prepared solution of 1 M sodium ethoxide (49 rnL). Once the addition was complete the reaction mixture was heated at reflux for 3 h. The llli~lulc was cooled and the precipitate was filtered. The salt was dissolved in methanol (60 mL), to it was added water (500 mL) and acetic acid (2 mL) to yield the title compound as a yellow solid (10.4 g, 76%): mp 94-95 ~C; lH NMR (400 MHz, CDC13) o 4.48 (q, J = 7.1 Hz, 2 H), 4.06(s,4 H), 3.26 (t, J = 6.5 Hz, 2 H), 3.02 (s, 2 H), 2.81 (s, 3 H), 2.02 (t, J = 6.5, 2 H), 1.47(t, J = 7.1 Hz, 3 H); MS (ESI) m/z 350 [M + H]+; Anal. Calcd. for C17HlgNO5S; C, 58.44; H, 5.48; N, 4.01; Found: C,58.34; H, 5.46; N, 3.86.
d) Ethyl 7,7-Ethylenedioxy4-trifluoromethylsulfonyloxy-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3--b]pyridine-3-carboxylate To a solution of colllyoulld of F.x~Tnple 3(c) (5.0 g, 14.3 mmol) in pyridine (50 mL) was added dropwise triflic anhydride (4.0 g, 14.2 mmol). The reaction ~Lule stirred at 0 ~C for 4 h until complete. The reaction mixture was washed with aqueous copper sulfate solution (3x) followed by water (2x), and brine (2x).
The organic layer ev~oldted, dried over anhydrous sodium sulfate and concentrated in vacuo. Puri~lcation by flash chromatography (silica gel, 1: 1 hexane: ethyl acetate) yielded the title compound as a light yellow solid (3.7 g, 54%): mp 133-134 ~C; lH
NMR (400 MHz, CDC13) o 4.43 (q, J = 7.2 Hz, 2 H), 4.06(s, 4 H), 3.16 (t, J = 6.5Hz, 2 H), 3.10 (s, 2 H), 2.77 (s, 3 H), 2.03 (t, J = 6.8 Hz, 2 H), 1.41 (t, J = 7.1 Hz, 3 H); MS (ESI) m/z 482 [M + H]+; Anal. Calcd- for Cl8Hl8F3NO7S2; C, 44.90; H~
3.77; N, 2.91; Found: C, 45.03; H, 3.62; N, 2.89.
e) 8,8-Ethylenedioxy-2,3,7,8,9,10-hexahydro-4-methyl- 1 H-benzo[b]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one To a solution of compound of Example 3(d) (2.4 g, 5.0 mmol) in methanol (40 mL) at room temperature was added hydrazine monohydrate (4.1 g, 82.3 mmol).
The reaction mixturê was heated at reflux for 3 h. The mixture was cooled then partitioned between pH 7 aqueous buffer and ethyl acetate. The organic layer was - 21 -CA 022l264~ l997-08-08 dried over anhydrous sodium sulfate, filtered, concentrated in vacuo and recyst~ 7çd from methanol/ethyl a~etate to yield the title compound as a light yellow solid (0.99 g, 60%). lH NMR (400 MHz, d4-MeOH) o 4.05 (s, 4 H), 3.15 (t, J=6.5Hz,2H),3.04(s,2H),2.82(s,3H),2.06(t,J=6.5Hz,2H); MS(ESI)m/z 318 [M + H]+; Anal. Calcd. for ClsHlsN3O3SØ25 H2O: C, 55.97; H, 4.85; N, 13.05; Found: C, 55.85; H, 4.75; N, 13.30.

Example 4 Pl ~y~ dlion of 4-r4-(4-Methylbenzoyl)benzoyllphenylacetaldehyde (Colllpol"ld 4) OHC ~ -- ~ ~ CH3 a) Methyl 4-(4-methylbenzoyl)ben7o~t~
A solution of methyl terephthaloyl chloride (6.2 g, 31 mmol) in 250 mL of toluene was treated with ~ minllm chloride (8.0 g, 60 mmol) at 0~C under an argon atmosphere. The stirring ll~ UlC was warmed to 35~C for 0.5 h. and then added slowly to 100 g of ice, followed by 150 mL of ethyl acetate, 50 mL of conc. HCI,and 50 mL of water. The phases were separated, and the aqueous portion was extracted twice with 100 mL of ethyl acetate. The combined organic portionswere washed with water (2 x 75 mL) and brine (1 x 75 mL), dried over m~nçsillm sulfate, filtered, and concentrated to a white solid. Recryst:~11i7~tion from ethyl acetate and hexane afforded 6.0 g (79%) of the title compound as white needles.
mp. 117-118~C; lH NMR (400 MHz, CDC13) ;~ 8.15 (d, J = 8.35 Hz, 2H), 7.83 (d, J
= 8.30 Hz, 2H), 7.73 (d, J =.8.18 Hz, 2H), 7.31 (d, J = 8.04 Hz, 2H), 3.98 (s, 3H), 2.46 (s, 3H); MS (ESI) m/z 255 (M+H)+.
b) 4-(4-Methylbenzoyl)benzoic acid A stirring solution of methyl 4-(4-methylbenzoyl)benzoate (5.00 g, 20.0 mmol in 150 rnL of 2: 1 THF: water at 65~C was treated with lithium hydroxide monohydrate (2.0 g, 48 mmol). After a period of 0.5 h the cloudy reaction mixture was allowed to cool to room temperature and treated with ethyl acetate (300 mL) and 10% HCl (aq.). The organic phase was separated, washed with water (2 x 50 mL) and brine (1 x 50 mL), dried over magnesium sulfate, filtered, and concentrated to a white foam. IH NMR (400 MHz, CDC13) o 8.22(d, J = 8.34 Hz, 2H), 7.81 (d, J
= 8.31 Hz, 2H), 7.73 (d, J =.8.15 Hz, 2H), 7.31 (d, J = 8.00 Hz, 2H), 2.46 (s, 3H).

CA 0221264~ 1997-08-08 c) 4-t4-(4-Methylbenzoyl)benzoyl]anisole A solution of compound of Example 4(b) in 250 mL of toluene was treated with oxalyl chloride (21.8 g, 0.17 mol). The resulting mixture was heated to reflux for 2 h, then concentldtt;d and allowed to stand overnight at 0.5 mrn Hg and 25~C.
5 This solid was then dissolved in 100 mL of anisole and treated with ~luminum chloride (11.2 g, 84 mmol) at 0~C. The ll~i~lul~; was heated to 70~C for 1 h and then added slowly to 100 g of ice, followed by 150 ml of ethyl acetate, 50 mL of conc.
HCl, and 50 rnL of water. The phases were separated and the aqueous portion was extracted with 100 mL of ethyl acetate. The combined organic extracts were washed with water (2 x 75 ml) and brine (1 x 75 ml), dried over m~.. e~ sulfate, filtered, and concentrated to a white solid. Recryst~lli7~tion from ethyl acetate and hexane yielded 4.6 g (70%) of the title compound. mp. 167-169~C; lH NMR (400 MHz, CDCl3) ;j .7.8-7.9 (m, 6H), 7.77 (d, J = 8.06 Hz, 2H), 7.32 (d, J = 8.01 Hz, 2H), 7.0 (d, J = 8.74 Hz, 2H), 3.92 (s, 3H), 2.47 (s, 3H); MS (ESI) 7n/z 331 (M+H)+.
d) 4-[4-(4-Methylbenzoyl)benzoyl~phenol A solution of compound of Example 4(c) (700 mg, 2.12 mmol) in 20 ml of dichlorometh~ne was treated with ~lllminllm chloride (1.0 g, 7.5 mmol) and 7.0 rnL
of 1.0 M boron trichloride solution in dichlorom~th:~ne and heated to reflux for 1 h.
The ll~ Ule was then diluted with 100 mL of dichlorom~th~n.- and washed with 10% HCl (aq) (1 x 25 mL), water (1 x 25 ml), and brine (1 x 25 rnL). The organicphase was dried over m~gnt~ lm sulfate, filtered, and concentrated to a dark residue which was subjected to flash chromatography (silica gel, elution with 1: 1 ethylacetate: hexane) to yield 550 mg (82%) of the title compound. IH NMR (400 MHz, CDC13) o .7.8-7.9 (m, 6H), 7.77 (d, J = 8.05 Hz, 2H), 7.32 (d, J = 8.01 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H), 2.47 (s, 3H).
e) 4-t4-(4-Methylbenzoyl)benzoyl]phenyl trifluoromethylsulfonate A solution of compound of Fx~mple 4(d) (320 mg, 1.0 mmol) in THF (20 mL) was treated with sodium hydride (40 mg, 1.67 mmol) and N-phenyltrifluorom~-th~neslllfonimide (500 mg, 1.40 mmol) at 0 ~C. The reaction mixture was allowed to warm up to room temperature and was then stirred for 18 h.
room temperature. The reaction was then partitioned between ethyl acetate and brine; layers were separated and the organic extract was dried over m:~gnecium sulfate and evaporated. Purifi~tion by flash chromatography (silica gel, 80:20 hexane: ethyl acetate) afforded the title compound (300 mg, 66%) . mp. 180- 181 ~C;
lH NMR (400 MHz, CDC13) o 7.96 (d, J = 8.6 Hz, 2 H), 7.89 (s, 4 H), 7.76 (d, J =8.1 Hz, 2 H), 7.45 (d, J= 8.6 Hz, 2 H), 7.33 (d, J= 8.1 Hz, 2 H), 2.47 (s, 3 H). f) 4-[4-(4-Methylbenzoyl)benzoyl]phenylacetaldehyde CA 0221264~ 1997-08-08 To a solution of compound of Example 4(e) (445 mg, 1.0 mmol) in DMF (10 mL) was added allyltributyltin (0.35 mL, 1.12 mmol), bis(triphenylphosphine)palladium(II) chloride (55 mg, 0.077 mmol) and lithium chloride (125 mg, 2.95 mmol). The reaction mixture was heated to 90 ~C for 1 h, and 5 then allowed to cool to room te~ eld~ulc before being partitioned between ethyl acetate and brine. The organic layer was dried over m~gnPsium sulfate and concentrated to a residue con~i.cting of the desired product, 3-[4-[4-(4-methylbenzoyl)benzoyl]phenyl]-1-propene, and tin-cont~ining by-products. This material was subjected to flash chromatography (silica gel, elution with 95:5 10 hexane: ethyl acetate) which removed most, but not all, of the tin i~ ufllies. A
second chromatography (gradient 5% to lQ% ethyl acetate in hexane) yielded 100 mg (30%) of clean olefin, which was then dissolved in dichloromethane/methanol (3: 1, 16 rnL) at -78 ~C. Ozone was bubbled through this solution for 5 min. Thereaction was quenched with five drops of dimethyl sulfide and stirring continued for 15 30 min at -78 ~C. The solvent was e~/~oldt~d and the res-llting m~teri~l purified by flash chromatography (silica gel, elution with gradient 85:15 to 75:25 hexane: ethyl acetate) to yield the title compound (40 mg, 40%). mp. 188-190~C; IH NMR (400 MHz, CDCl3) ~ 9.83 (s, 1 H), 7.88 (s, 4 H), 7.86 (d, J = 8.1 Hz, 2 H), 4.03 (s, 4 H), 3.73(s,3H),3.76(t,J=6.0Hz,2H),3.00(s,2H),2.80(s,3H),2.03(t,J=6.0 20 Hz, 2 H); MS (ESI) m/z 343 (M+H)+.

Exarnple 5 Preparation of 1 ~4-Dimethyl-8.8-ethylenedioxy-2.3.7.8.9.10-hexahydro- 1 H-benzorblthienor2.3-blpyrazolor3~4-dlpyridin-3-one (Compound 5) ~0 1,4-Dimethyl-8,8-ethylenedioxy-2,3,7,8,9,10-hexahydro-lH-benzo[b]thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-one A solution of compound of Example 3(d) (0.4 g, 0.83 mmol) in methanol (6.7 mL) at room telllpeldlule was treated with methylhydrazine (0.16 g, 3.45 mmol) 30 and the mixture is heated at reflux for 2 h. The mixture was cooled and the precipitate, cont~ining 150 mg of the 2,4-dimethyl regioisomer, filtered. The filtrate was evaporatewd and purified by flash chromatography (silica gel, elution with CA 0221264~ 1997-08-08 80:20:5 ethyl acetate m.-th~nol:acetic acid) to provide the title compound as a yellow solid (22 mg). IH NMR (400 MHz, CDC13) o 4.03 (s, 4 H), 3.73 (s, 3 H), 3.76 (t, J
=6.0Hz,2H),3.00(s,2H),2.80(s,3H),2.03 (t,J=6.0Hz,2H);MS (ESI)m/z 332 (M+H)+.
Example 6 P~ )~dlion of 4-carboxy-benzophenone-4-carboxamido-trans4-methyl-cyclohexyl-N-hexyl carboxamide (Compound 6) o o HOzC ~b~N_O- H~
a) N-t-butyloxy carbonyl-trans-4-aminomethyl cyclohexyl carboxylic acid Aqueous sodium hydroxide (lN, 100 ml, 100 mmol) was added to a solution of 4-trans-aminomethyl-cyclohexyl-carboxylic acid (9.0g, 60 mmol), in dioxane (100 ml), water (100 ml) at 0 degrees C. Boc anhydride (15.9 g, 66 mmol) was 15 added and the reaction was warmed to rt and stirred overnight. The solution was concentrated to 50 ml, then was diluted with EtOAc (100 ml) and acidified to pH 2 with adqueous KHSO4 (lN). The organic layer was then extracted with water (100 ml) two times, and the organics were concentrated in vacuo. The solid was recryct~lli7~cl from EtOAc/ hexanes to yield 9.2g + 3.4g (second crop) of a white solid. (80% yield). MS (ES) m/e 242 [M+H]~.
b) N-t-butyloxy carbonyl-trans-4-aminomethyl cyclohexyl (Kaiser oxime resin) carboxylate Kaiser oxime resin (20 g, 0.7 mmol/g loading, Advanced Chem Tech) was added to a solution of N-t-butyloxy carbonyl-trans-4-aminomethyl cyclohexyl carboxylic acid (5.0 g, 20 mmol) and DCC (4.4 g, 20 mmol) in methylene chloride (200 ml) and was gentle mixed at rt overnight. The solid was filtered and collected, then washed with methylene chloride (S x 100 ml). Then the resin was resuspendedin methylene chloride (200 ml), and N-t-butyloxy carbonyl-trans-4-aminomethyl cyclohexyl carboxylic acid (5.0 g, 20 mmol) and DCC (4.4 g, 20 mmol) were added and the reaction was gently mixed overnight at rt. The solid was filtered and collected, then washed with methylene chloride (5 x 100 ml), then was dried overnight under vacuum. IR (KBr, crn~')=1820, 1771, 1520.
c) trans-4-aminomethyl cyclohexyl (Kaiser oxime resin) carboxylate CA 0221264~ 1997-08-08 N-t-butyloxy carbonyl-trans-4-aminomethyl cyclohexyl (Kaiser oxime resin) carboxylate (20 g) was suspended in methylene chloride (100 ml) and TFA (25 ml) was added. The reaction was gently mixed for 0.5 h, then the solid was filtered and collected, then was washed with with methylene chloride (5 x 100 ml), then was dried overnight under vacuum. IR (KBr, cm~l)=3150, 1770, 1526 d) 4-carboxy-benzophenone-4-carboxamido-trans-4-methyl-cyclohexyl-(Kaiser oxime resin) carboxylate Trans-4-~minnm.othyl cyclohexyl (Kaiser oxime resin) carboxylate (200 mg) was suspended in DMF (3.0 ml) and N-methyl morpholine (0.2 ml) and 4, 4'-benzophenone dicarboxylic acid (190 mg, 0.7 mmol) and HBTU (265 mg, 0.7 mmol) was added and the reaction was gently mixed for 3 h. The solid was filtered and collected, then was washed with with DMF (3 x 20 ml), then water (3 x 20 ml), then was resuspended in DMF (3.0 ml) and N-methyl morpholine (0.1 ml) and 4,4'-benzophenone dicarboxylic acid (0.35 mmol) and HBTU (0.35 mmol) was added and the reaction was gently mixed for 3 h. The solid was filtered and collected, then was washed with with DMF (3 x 20 ml), then water (3 x 20 ml), then methylene chloride (5 x 20 ml), then was dried under vacuum.
e) 4-carboxy-benzophenone-4-carboxamido-trans-4-methyl-cyclohexyl-N-hexyl carboxamide 4-carboxy-benzophenone-4-carboxamido-trans-4-methyl-cyclohexyl-(Kaiser oxime resin) carboxylate (200 mg) was suspended in methylene chloride (3.0 ml) and hexyl amine (0.3 mmol) was added. The reaction was gently mixed for 3 h thenwas filtered, and the filtrate was concentrated in vacuo to yield the title compound:
MS (ES) m/e 493 [M+H]~.
Example 7 P.c~aldtion of 4-nitro-ben7zlrnirlQ-trans-4-methyl-cyclohexyl-N-hexyl carboxamide (Compound 7) 02N ~ N O H

4-nitro-ben7~rnido-trans-4-methyl-cyclohexyl-N-hexyl carboxamide Following the procedure of Example 6(a)-(e), except substituting 4-nitro benzoic acid for and 4, 4'-benzophenone dicarboxylic acid, the title compound was prepared: MS (ES) m/e 390 [M+H]'. t Example 8 Plel)al ation of 4-~- et~mido-benzarnido-trans-4-methyl-cyclohexyl-N- 1 -(arnino-R-2-(methoxy methyl)-pyrrolidine) carboxamide (Compound 8) O ~HN~C¦~ H r2 o Following the procedure of Example 6(a)-(e), except ~ub~liLuLillg 4-acetamido- benzoic acid for and 4, 4'-benzophenone dicarboxylic acid and R- 1-arnino-2-(methoxy methyl)- pyrrolidine (RAMP) for hexyl arnine, the title compound was prepared: MS (ES) m/e 331 [M+H]~.
Example 9 ;~;~dLion of 4-formyl-E-çinll~mi(lo-trans-4-methyl-cyclohexyl-N-(propyl) carboxarnide (Colllyoulld 9) OHC~N~ N--~

Following the procedure of Example 6(a)-(e), except substituting 4-forrnyl cinn~mi~. acid for and 4, 4'-benzophenone dicarboxylic acid and propyl amine forhexyl amine, the title compound was prepared: MS (ES) m/e 357 [M+H]~.

Example 10 20Plc~dtion of 2.3.7.8.9~10-Hexahydro-4-methyl-lH-benzorblthienor2~3-blpyrazolor3~4-dlpyridin-3-one (Compound 10) C~CH"
a) Ethyl 4-Hydroxy-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3--b]pyridine-2-carboxylate 25A solution of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (8.9 g, 39 mmol) and ethyl 3-ethoxycrotonate (12.4 g, 78 mmol) in toluene (300 mL) was treated with camphorsulfonic acid (0.78 g, 3.4 mmol) and the CA 0221264~ 1997-08-08 reaction mixture was heated at reflux for 3 h using a Dean Stark trap. The mixture was then cooled to room tt;~ eldtule and was subsequently treatedwith a freshly prepared 1 M solution of sodium ethoxide (48 mL, 48 mmol). After addition was complete the reaction llli~lul'~ was heated at reflux for 3 h. The mixture was cooled, S conc~ dl~d and the residue dissolved in ethyl acetate. Acetic acid (2 mL) was added, solvent ~v~o-dl~d and resulting solid triturated with methanol to yield the title compound as an off-white solid (8.4 g, 74%): mp 140 ~C; IH NMR (400 MHz, CDC13) o 4.48 (q, J = 7.2 Hz, 2 H), 3.04 (br s, 2 H), 2.81 (s, 3 H), 2.80 (br s, 2 H), 1.87 (br s, 4 H), 1.47 (t, J = 7.2 Hz, 3 H);; Anal. Calcd. for C1sH17NO3S: C, 61.83;
H, 5.88; N, 4.81; Found: C, 61.69; H, 5.81; N, 4.73.
b) Ethyl 4-Chloro-2-methyl-5,6,7,8-tctrahydrobenzotb]thieno[2,3--b]pyridine-2-carboxylate A solution of compound of Example lO(a) (3.0 g, 27.4 mmol) in phosphorus oxychloride (100 mL) was refluxed for 3.5 hours. The phosphorus oxychloride was 15 removed under vacuum and the residual oil was dissolved in ethyl acetate, washed with 5% aqueous sodium bicarbonate and dried over anhydrous sodium sulfate.
Evaporation of the solvent provided the title compound as a crystalline solid (8.5 g, 95%): mp 65-66 ~C; lH NMR (400 MHz, CDC13) o 4.47 (q, J = 7.1 Hz, 2 H), 3.10 (brs,2H),2.85(brs,2H),2.60(s,3H), 1.89(brs,4H), 1.43(t,J=7.1 Hz,3H);
Anal. Calcd. for ClsH16ClNO2SØ125 H2O: C, 57.73; H, 5.25; N, 4.49; Found: C, 57.69; H, 5.08; N, 4.30.
c) 2,3,7,8,9,10-Hexahydro-4-methyl- lH-benzo[b]thieno~2,3-b]pyrazolo[3,4-d]pyridin-3-one A solution of compound of Example lO(b) (2.0 g, 6.4 mmol) in methanol (50 mL) was treated with hydrazine monohydrate (10 mL) and the resulting llli~lu.c; was heated at reflux for 16 h. The reaction was poured overdiluted aqueous hydrochloric acid and the title compound precipitated as a yellow solid (1.8 g). lH NMR (400 MHz, d4-MeOH) ~ 3.01 (br s, 2 H), 3.00 (s, 3 H), 2.92 (br s, 2 H), 2.00 (br s, 4 H); Anal. Calcd. for Cl3Hl3N3OS.HClØ25 H2O: C, 52.00; H, 4.87; N, 13.99; Found: C, 51.92; H, 5.01; N, 13.70.

Example 11-Protocol for the Determination of the Potency of SH2 Domain Antagonists The inhibitory activity of compounds at the different human SH2 domains 35 was determined in vitro using SH2 domains expressed as fusion proteins in E. coli.
The SH2 domains used herein were the human forms of the src SH2 domain, Grb2 CA 0221264~ 1997-08-08 SH2 domain, lck SH2 domain, fyn SH2 dom:~in, SH-PTP2 SH2 domain, p85 SH2 domain and hcp SH2 domain.
The fusion proteins cons~ining the src, lck and hcp SH2 domains were expressed as the general sequence: DETl-DET2-spacer-ek-SH2, where DET1, 5 DET2, spacer, ek and SH2 are as described below. DET1 ("defined epitope tag 1") (SEQ ID NO: 1) is an 11 amino acid sequence found in the Human Irnmunodeficiency Virus Type 1 (HIV-l) envelope protein gpl20 (or gpl60).
Monoclonal antibodies to various epitopes of HIV-l gpl20 (or gpl60) are known inthe art, see, for example U.S. Patent 5,166,050. One plcfellc;d çx~mple is monoclonal antibody 178.1 (see, e.g., Thiriart et al., J. Irllmunol.~ 143:1832-1836 (1989)), which was prepared by i.,.. ,.i~ ion of mice with a yeast-expressed HIV-l gpl60 molecule from strain BH10 (Ratner et al., Nature, 313:277-284 (1985)). This tag was used for detection of expression (by Western blot), for purific~tion of the protein (by affinity chromatography), and for configllring assays in which the fusion protein was captured or immobilized using the 178.1 antibody. DET2 is a hexa-histidine sequence tag (SEQ ID NO: 2) which binds to nickel-cont~ining resins and was used for pnrific:~tion purposes. Spacer (SEQ ID NO: 3) was utilized to design a BarnH1 restriction site at the intlir~tr~l position of the construct. The term -ek-refers to a recognition sequence (SEQ ID NO: 4) for the enterokinase protease which 20 provides for the optional removal of the tags from the SH2 domain, thus producing an SH2 domain that contaills no extraneous amino acids. SH2 domains which contain no extraneous amino acids are preferable to tagged protein for crystallography studies. SH2 refers to the SH2 ~om~ins of different proteins.
The DNA sequence encoding each DETl-DET2-spacer-ek-SH2 was 25 designed such that the indicated restriction sites (BarnHl and XbaI) flank the spacer-ek-SH2 region, thereby allowing different spacer-ek-SH2 contructs to be readily substituted into any one of the vectors described in Procedures 2 or 3 below to create a DETl-DET2-spacer-ek-SH2 tagged protein. The DNA sequence encoding each DET1-DET2-spacer-ek-SH2 constructs was also ~irsj~n.o~ such that the entire tagged 30 SH2 domain can be moved as an NdeI-XbaI fragment into any expression vector cont~ining an NdeI site at an ~plo~liate distance downstream of E. coli CA 0221264~ 1997-08-08 WO 96/24343 PCTtUS96/01964 transcription and translation regulatory sequences and a downstream cloning sitecompatible with XbaI. Although any suitable vector would yield similar results(e.g., pET-1 la; Novagen, Inc.), the vector used in the instant experiments was E. coliexpression vector pEAlKnRBS3. This vector is a derivative of the series of vectors 5 described in Sh~t7m~n, A, Gross, M, and Rosenberg, M, 1990, "Expression using vectors with phage lambda regulatory sequences", In: Current Protocols in Molecular Biology (F.A. Ausubel et al, eds.), pp. 16.3.1 -16.3.11, Greene Publishing and Wiley-Interscience, N.Y. (hereinafter F.A. Ausubel et al.). The specific vector pEAlKnRBS3 is described in Bergsma et al, 1991, J. Biol. Chem. 266:23204-23214.
The procedures below describe the expression of chicken src, human src,human lck and human hcp SH2 domains. First, the chicL-~n src SH2 domain was expressed as DETl-DET2-spacer-SH2. Then, the others were inserted into this vector in place of chicken src to express proteins in the form DETl-DET2-spacer-15 ek-spacer-SH2.

Procedure 1: Cloning and Expression of chicl~t n src SH2 domain cont~ining tags DET1 and DET2 (DETl-DET2-spacer-SH2).
A DNA sequence encoding the tagged protein DETl-DET2-spacer-SH2 was 20 PCR ~mplified from a cDNA clone c~-nt~ining the chicken src gene (pSH; Levy et al 1986. Proc. Natl. Acad. Sci. USA 83:4228) by methods well known to those skilledin the art by using the following ~

CCACCACCACGGGATCCCCGCTGAAGAGTGGTAC l~l T 3' (SEQ ID NO: 17) The llnclerlined sites are an NdeI recognition site (5') and a BamHI
recognition site (3').

5 ' GGAATTCTAGATTACTAGGACGTGGGGCAGACGTT 3 ' (SEQ ID NO: 18) ,-- ~

CA 0221264~ 1997-08-08 WO 96124343 P~T/US96/01964 The lln-3erlint-d region is an XbaI recognition site.
The PCR product was digested with NdeI and XbaI, followed by isolation of the digested fragment on an agarose gel. The fragment was ligated into NdeI-XbaI-5 digested pEAlKnRBS3 vector (Bergsma et al, supra) that had been agarose gelpurified as a 6.5 kbp fr~gm~nt The ligation reaction was used to transform E. coli MM294cI+ (F.A. Ausubel et al., supra). A pl~cmi~l cont~ining an insertion of thecorrect fragment was i~1entified and confirm~ocl by DNA sequencing. The result~nt plasmid encodes DETl-DET2-spacer-SH2 under the control of the phage lamda PL
10 promoter and regulatory system. Plasmid DNA was purified from MM294cI+ and used to transform E. coli strain AR120. In this host strain, expression of the phage promoter can be in~l~7cecl by addition of nalidixic acid to the growing culture as described in F.A. Ausubel et al, supra. N~litlixir acid induction of AR120 co~ g this plasmid, followed by analysis of the cellular proteins on an SDS-15 polyacrylamide gel stained with Coom~cci~ Blue (F.A. Ausubel et al., supra),resulted in a~pe~ce of a protein band with an a~el t molecular weight of 15,000; this band was not seen in llnin~lnce-l cells or in intlllce~l cells cont~ining pEAlKnRBS3 lacking the PCR amplified fr~gm~nt Western blotting confirmed that the inclllce~ protein band reacted with the anti-DET1 monoclonal antibody 178.1.

Procedure 2: Cloning, expression and purific ~tion of human src SH2 domain cont~ining tags and an enterokinase proteolytic cleavage site (DET1-DET2-spacer-ek-src SH2).
A DNA sequence encoding protein ek-src SH2 was PCR amplified from a cDNA clone cont~ininp the human src gene (c-src SH2 DNA sequence identical to that described in Takeya,T. and Hanafusa, H, 1983 Cell 32:881-890) using the following primers:
A

30 5' CGGGATCCTGGACGACGACGACAAAGCTGAGGAGTGGTATTTT 3' (SEQ ID NO: 19) CA 0221264~ 1997-08-08 The underlined site is a Ba~HI recognition site.

5' GGAATTCTAGACTATTAGGACGTGGGGCACACGGT 3' (SEQ ID NO: 20) The un~llorlin~l region is an XbaI recognition site.

The PCR product was digested with BamHI and XbaI, followed by isolation of the digested fragment on an agarose gel. The fragment was ligated into BamHI-10 XbaI-digested expression vector co-~t~;r i--g the tagged chic~n src gene DETl-DET2-spacer-SH2 described in Procedure 1 above. In that vector, the BamHI site is located between the coding regions for DET2 and SH2, and the XbaI site is located after the 3' end of the SH2 coding region. The ligation reaction was used to transform E. coli MM294cI'. The construct DETl-DET2-spacer-ek-src SH2 was 15 confirmlod by DNA seqllen~ing (SEQ ID NO: 5) and in-lllced in E. coli strain AR120 as described in Procedure 1 above. A Coomassie-Blue-stained, Western-blot-positive intlut~e~l protein band with an al~l,~cnt molecular weight of 16,000 was observed after n~ lixic acid induction.
Cells were lysed at neutral pH by sonication in the presance of Iysozyme.
20 After centrifugation, the soluble extract was chromatographed on a Ni~NTA
column. After washing the column with equilibration buffer (Tris buffer pH 8 cont~ining 0.5 M NaCl) and the same buffer cont~ining 15 mM imitl~7O1e, the protein was eluted in highly purified form with 25 mM imicl~7O1e in equilibration buffer. The SH2 dom~in, purified in this fashion, was found to bind with high 25 affinity in a specific, saturable fashion to the ~lo~liate pY peptide in the "Binding Assays" described below, demonstrating that the tag did not interfere with function.
This expressed fusion protein, DETl-DET2-spacer-ek-src SH2, was utilized in the "Binding Assays" described below in order to deterrnine the specificity of compounds to selectively inhibit the human src SH2 domain.

CA 0221264~ 1997-08-08 WO 96/24343 PCT/US96/0196"

Procedure 3: Cloning and expression of human lck SH2 domain cont~ining tags and an enterokinase proteolytic cleavage site (DETl-DET2-spacer-ek-lck SH2).
A DNA sequence encoding protein ek-lck SH2 was PCR ~mplified from a cDNA clone cont~ g the human lck gene (Genbank accession number M3688 1 ) S using the following ~JlhllCl~i S' CGGGATCCTGGACGACGACGACAAAGAGCCCGAACCCTGGTTCTT 3 ' (SEQ ID NO: 21) The underlined site is a BamHI recognition site.

S' GCTCTAGACTATTACTGGGGCTTCTGGGTCTG 3' (SEQ ID NO: 22) The lln~l~rlinto.d region is an XbaI recognition site.
The PCR product was digested with BamHI and XbaI, followed by isolation of the digested fragment on an agarose gel. The fragment was ligated into BamHI-XbaI-digested expression vector col.~ )g the tagged chic~ n src gene DET1-DET2-spacer-SH2 described in Procedure 1 above. In that vector, the BamHI site is located in between the coding regions for DET2 and SH2, and the XbaI site is 20 located after the 3' end of the SH2 coding region. Thus, the ek-lck SH2 sequence replaced the src SH2 sequence in the above vector. The ligation reaction was used to transform E. coli MM294cI'. The construct con1~inin~ DET1-DET2-spacer-ek-lck SH2 was confirm~A by DNA seq--en~in~ (SEQ ID NO: 6) and ind~lce~l in E. colistrain AR120 as described in Procedure 1 above. A Coomassie-Blue-stained, 25 Western-blot-positive in(lllcecl protein band with an ~p~cnt molecular weight of 17,000 was observed after nalidixic acid induction.
Cells were lysed at neutral pH by sonication in the presance of lysozyme.
After centrifugation, the soluble extract was chromatographed on a Ni~NTA
column. After washing the column with equilibration buffer (Tris buffer pH 8 30 contz~ining 0.5 M NaCl) and the same buffer cont~inin~ 15 mM imidazole, the protein was eluted in highly purified form with 25 mM imicl~7ole in equilibration -CA 0221264~ 1997-08-08 buffer. The SH2 ~lQm~in, purified in this fashion, was found to bind with high affinity in a specific, saturable fashion to the ~p~ iate pY peptide in the "Binding Assays" described below, demonstrating that the tag did not interfere with function.
This expressed fusion protein, DETl-DET2-spacer-ek-lck SH2, was utilized in the S "Binding Assays" described below in order to ~ termine the specificity of compounds to selectively inhibit the human lck SH2 domain.

Procedure 4: Cloning and expression of human hcp SH2 domain cont~ining tags and an enterokinase proteolytic cleavage site (DET1-DET2-spacer-ek-hcp SH2).
A DNA sequence encoding protein ek-hcp SH2 (hcp SH2 DNA sequence identical to that described in Shen, S-H. Nature (1991) 352: 736-739) was reverse transcriptase-PCR amplified from human fetal liver RNA. RNA isolation used Tri-Reagent (Molecular Research Center Inc.) and the Reverse Transcriptase system (GIBCO-BRL) according to the m~nllf~cture's instructions. PCR was carried out using the following primers:

5' GAAGATCTTGGACGACGACGACAAATCCCGTGGGTGGTTTCAC
3'(SEQ ID NO: 23) The lln~l-rlined site is a BglII recognition site.

S' GCTCTAGACTATTAACTAGTGGGATCGGAGCA 3' (SEQ ID NO: 24) The lln~l~rlined region is an XbaI recognition site.
The PCR product was digested with BglII and XbaI, followed by isolation of the digested fragment on an agarose gel. The fragment was ligated into BamHI-XbaI-digested expression vector cont~ining the tagged human src gene DET1-DET2-spacer-ek-src SH2 described in Procedure 2 above. In that vector, the BamHI site is located in between the coding regions for DET2 and ek, and the XbaI
site is located after the 3' end of the SH2 coding region. Thus, the ek-hcp SH2 sequence replaced the ek-src SH2 sequence in the above vector. The ligation _ CA 0221264~ 1997-08-08 reaction was used to transform _ coli MM294cI+. The construct contz~ining DET1-DET2-spacer-ek-hcp SH2 was confirrned by DNA sequencing (SEQ ID NO: 7) and used to transform ~ coli GI698 (Invitrogen Corporation, San Diego, CA). Induction of the phage lambda promoter was inrillced by addition of tryptophan to the culture S mt--lium to 10 mg/ml, per the manufacture's instructions. A Coomassie-Blue-stained, Western-blot-positive in~ ecl protein band with an apparent molecular weight of 15,000 was observed after tryptophan induction of cells growing at 30~ C.
Cells were lysed at neutral pH by sonication in the presance of lysozyme.
After centrifugation, the insoluble pellet was solubilized with 8 M urea in Tris buffer 10 pH 8 and bound onto a Ni+~NTA colurnn. The resin was washed with equilibration buffer (Tris buffer pH 8 co~ i..ing 0.5 M NaCl, 8 M urea and S rnM BME) and the sarne buffer c~nt~ g 15 mM imitl~7ole. The protein was refolded on the column during the removal of urea in the presence of 5 mM BME and the purified refoldedprotein eluted with 30~ mM imid~ole in Tris buffer pH 8. The SH2 rlom~in~
15 purified in this fashion, was found to bind with high affinity in a specific, saturable fashion to the ~ u~liate pY peptide in the "Binding Assays" described below, demonstrating that the tag did not hltc.rclc with function and that the protein was refolded ~uccçs~fully. This expressed fusion protein, DET1-DET2-spacer-ek-hcp SH2, was utilized in the "Binding Assays" described below in order to deterrnine the 20 specificity of compounds to selectively inhibit the human hcp SH2 domain.

Fusion proteins having the structure GST-X-SH2 were prepared as described in the GST gene fusion kit system available from Pharmacia (New Jersey). GST is the tagging sequence glutathione s-transferase epitope (SEQ ID NO: 8) for fyn, Grb2 25 and SH-PTP2 and is the tagging sequence glutathione s-transferase epitope (SEQ ID
NO: 9) for p85. SH2 refers to the SH2 domains of fyn, Grb2, p85 and SH-PTP2 which were expressed and purified using glutathione Sepharose 4B (Pharmacia) according to "Current Protocols in Molecular Biology", ed. FM Ausubel et al., pub.
John Wiley and Sons, Inc., (1995), p 16.7.1. X is an ~plu~liate linker, preferably of 30 6 to 21 base pairs, used to keep the SH2 construct in frame and complement cloning.
As such, the sequence of X is not critical. One skilled in the art can readily construct CA 0221264~ 1997-08-08 the applupliate linker. The DNA sequence encoding each GST-X-SH2 fusion protein was designed such that the in-lic~tçd restriction sites (BamH1 and EcoRI) flank the SH2 region. The vector used in the instant experim~3nt~ was the E. coli expression vector pGEX-2T (Ph~l~n:~ri~) for fyn, Grb2 and SH-PTP2, and pGEX-3X
(Pharmacia) for p85. Each of these vectors result in SH2 constructs having additional C-te.rmin~l amino acids as described below.
The sequence encoding the SH2 domain of human fyn (amino acids 143-252) (Yamamoto, T. et al. Proc. Natl. Acad. Sci. USA 83, 5459-5463 (1986)) was cloned into the BamHI and EcoRI sites of the expression vector pGEX-2T. The SH2 domain including the additional C-terrnin~l amino acids leucine-threonine-asparagine-serine-serine (SEQ ID NO: 10) was cloned by PCR techniques known to those skilled in the art to yield the expressed fusion protein GST-X-fyn. This expressed fusion protein was then utilized in the "Binding Assays" described below in order to determine the specificity of compounds to selectively inhibit the human fyn SH2 domain.
Human p85 SH2 domain: The sequence encoding the SH2 domain of human p85 (amino acids 321-440) (Skolnik, E. et al., Cell 65, 83-90 (1991)) was clonedinto the BamHI and EcoRI sites of the expression vector pGEX-3X. The SH2 domain including the additional C-terrnin~l amino acids asparagine-serine-serine(SEQ ID NO: l l)was cloned by PCR techniques known to those skilled in the art to yield the expressed fusion protein GST-X-p85. This expressed fusion protein was then utilized in the "Binding Assays" described below in order to ~letermine thespecificity of compounds to selectively inhibit the human p85 SH2 domain.
Human SH-PTP2 SH2 domain: The sequence encoding the SH2 domain of human SH-PTP2 (arnino acids 1-106))(Bastien, L. et al., Biochem. Biophys. Res.
Commun. 196, 124-133 (1993)) was cloned into the BamHI and EcoRI sites of the expression vector pGEX-2T. The SH2 domain including the additional C-terminal amino acids gl~lt~mine-phenyl~l~nine-isoleucine-valine-threonine-aspartate (SEQ ID
NO: 12) was cloned by PCR techniques known to those skilled in the art to yield the expressed fusion protein GST-X-SH-PTP2. This expressed fusion protein was then CA 0221264~ 1997-08-08 utilized in the "Binding Assays" described below in order to ~lPtt-rmine the specificity of compounds to selectively inhibit the human SH-PTP2 SH2 domain.
Human Grb2 SH2 domain: The sequence encoding the SH2 domain of human Grb2 (amino acids 58-159) (Lowenctein, E. et al., Cell 70, 431-442 (1992))~ 5 was cloned into the BamHI and EcoRI sites of the expression vector pGEX-2T. The SH2 domain inrlu-ling the additional C-t~-rmin~l amino acids isoleucine-hicti~lin~-arginine-aspartate (SEQ ID NO: 25) was cloned by PCR techniques known to those skilled in the art to yield the expressed fusion protein GST-X-Grb2. A six nucleotide linker was used and resulted in the amino acids glycine and serine between the GST and SH2 domain. This expressed fusion protein was then utilized in the "Binding Assays" described below in order to ~lrlr~ 111;11~, the specificity of compounds to selectively inhibit the human Grb2 SH2 ~lom~in Binding Assays: The potency of compounds at the SH2 rlom~inC was determined based on the ability of such compound to selectively inhibit such SH2 domain from binding to its respective specific pY peptide.
The binding assays for the SH2 domains and pY peptides were performed in an ELISA-based 96 well plate assay. In Millipore 96 well filter plates, hydrophilic Durapore(~) (pore size 0.65um Cat. No. MADVN6550), was added 2 ul (50%
suspension) of Protein-G Sepharose (available from Pharmacia of N.J. Cat. No. 17-0618-01) and either 2 ul of 2 mg/ml of MAB 178.1 (for gp 120/SH2 domain fusion proteins src, lck and hcp) or 0.25 ul of anti-GST polyclonal antisera (available from Pharmacia of N.J.) (for GST/SH2 domain fusion proteins fyn, Grb2, p85 and SH-PTP2). 10 pmol of the subject SH2 domain fusion protein were added to their respective wells. The volume was brought to 100 ul with TBS-T (tris buffered saline plus 0.05% tween-20), inrub~te~ and shaken at room trmperature for 1 hr. then washed lx with TBS-T (4~C). 90 ul of TBS-T were then added to each well.
Specific pY biotinylated peptides were diluted to a concentration of 1.0 uM in TBS-T (these peptides can be obtained from Bachem Bioscience of Pennsylvania, Genosys Biotechnologies of Texas and California Peptide Research of California).10 ul was aliquoted per well to yield a final concentration of 0.1 uM (approx. the Kd CA 0221264~ 1997 - 08 - 08 WO 96/24343 PcTrus96lol964 for each SH2 domain/peptide pair~ and a final volume of 100 ul. The assay plateswere incubated until equilibrium binding was ~tt~inçcl (3 hr at 4~C with .ch~king) The assay plates were washed 2 X per well TBS-T (4~C), then 100 ul of SABC
(Strepavidin biotinylated horseradish peroxidase complex, available from the Zymed corporation of California cat. no. 93-0043, 1 drop reagent A (~Ll~L~vidin) and 1drop of reagent B (AH-biotin conjugated-horseradish peroxidase) per 10 ml of TBS-T, incubated at 37~C for 30 minutes, then cooled to 4~C) was added per well, then incubated at 4~C for 30-60 minutes. The plates were then washed 4 X with TBS-T
(4~C) (250 ul/well)/wash). 100 ul of 1 mg/ml OPD (o-phenylt1i~min~, Sigma Chemical Corporation, St. Louis Missouri) in Citrate Buffer was added per well. To stop development, 100 ul of 10% sulfuric acid was added per well. 150 ul from each well was then removed from the assay plate and placed in an ELISA plate. The A4,.,.
of each ELISA plate was then det~rmin.o~

Determination of (IC5") for Table I
Each control or compound was assayed in duplicate. The duplicates were averaged and the background subtracted and the m~xim~l values with no inhibitionwere taken from the plate, then all other data points were expressed as a percent of the m~xim~l value (or as % control). These % control data values were graphed inK~leitl~graph for Macintosh (Synergy Software). The curves on these graphs were nonlin~r curve fitted with the following equation F(x)=Emax/(l+(kd/conc)~slope),wherein the kd term represents the IC50 for each of the curves.

Determin~tion of (Ki) for Table II
The Ki for respective compounds is calculated via the following equation (see reference). This expanded equation must be used under the conditions of this assay, due to the fact that the pY biotinylated peptide is not in vast excess concentration (100X) over the SH2 domain fusion protein. The IC50 is an extrapolated value from a nonlinear curve fit using Kaleidagraph. Rtot and *D are known values for reagents input into the assay. KD generally must be CA 0221264~ 1997-08-08 exp~.rim~nt~lly dete~ ined for each combination of SH2 domain fusion protein and pY biotinylated peptide.

KI=(ICso- , 5 Rtot+Rtotl2((*D/(KD+*D))+(KD/(KD+*D+Rtot/2)))t( 1 +*D/KD+Rtot/KD((KD+*D
/2)/(KD+*D))) KI=(uM)KDof coll~t;LiLol ICso=(uM) ICso for inhibitor, derived via no~lin~.~r curve fit of coll.petiLion 10 selectivity assay data for each SH2 domain Rtot=(uM)total SH2 domain concentration within 1 assay (microtitre plate) well *D=(uM)conce~lL dLion of specific pY and biotinylated peptide for each SH2 domain KD=(uM)KD value for the specific pY and biotinylated peptide for each SH2 domain 15 IC50 is the concentration of inhibitor at which the response or signal is inhibited by 50%

KD is the dissociation constant for a ligand in a receptor/ligand interaction, normally equaling the concentration of ligand which is at 1/2 Vmax on a saturation binding 20 curve>

The pY peptide ligands used in the above Binding Assays are as follows:

Biotinylated pY peptide ligand cont~ining an aminocaproic acid (Aca) linker used25 for src, lck, and fyn SH2 dom~in~

Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu (SEQ ID NO: 13) Biotinylated pY peptide ligand cont~ining an aminocaproic acid (Aca) linker used30 for p85 SH2 CA 0221264~ 1997-08-08 WO 96/24343 PCT/US96/0196'1 Asp-Gly-Gly-pTyr-Met-Asp-Met-~Ser-Lys-Asp-Glu (SEQ ID NO: 14) Biotinylated pY peptide ligand cont~ining an aminocaproic acid (Aca) linker usedfor SH-PTP2 SH2 Glu-Asn-Gly-Leu-Asn-pTyr-Ile-Asp-Leu-Asp-Leu (SEQ ID NO: 15) Biotinylated pY peptide ligand cont5Jining an aminocaproic acid (Aca) linker used for hcp SH2 Thr-Pro-Pro-His-Leu-Lys-pTyr-Phe-Tyr-Phe-Val-Val-Ser-Asp-Ser-Gly (SEQ ID
NO: 16) Biotinylated pY peptide ligand colll~;,,ill~ an aminocaproic acid (Aca) linker used 15 for Grb2 SH2 Leu-Pro-Val-Pro-Glu-pTyr-Ile-Asn-Gln-Ser-Val (SEQ ID NO: 26) Results of Binding Assays:
20 Tables I and II illustrate the cross reactivity of SH2 antagonists at the in~ tPcl SH2 domains. From the results disclosed in these tables colllpoullds which have binding affinities/inhibitory concentrations which are greater than fifty-fold higher at the lck SH2 domain than the binding affinities/inhibitory concentrations at other SH2 domains can be readily identifiP-l -Table I

CROSS REACTIVITY OF Src SH2 DOMAIN ANTAGONISTS AT CLONED
HUMAN SH2 DOMAINS (IC~") - Compound Src Lck Fyn SH- p85Grb2 Hcp 6 uM 6 uM NI NI NI NI X
2 NI NI NI NI NI NI 0.9 uM
3 16.1 uM22.9 uM NI NI NI NI 1.2 uM
4 40 uM 163 uM NI X NI NI 30 uM
63 uM 100 uM NI NI NI NI 0.1 uM
6 20 uM NI NI X NI NI X
7 7.4 uM 383 uM NI NI NI NI NI
8 16 uM 126 uM NI NI NI NI >100 uM
9 131 uM 200 uM NI NI NI NI 12 uM
X X NI NI NI NI 1.2 uM

NI-No inhibition observed out to 300uM
X-not tested Table II

CROSS REACTIVITY OF Src SH2 DOMAIN ANTAGONISTS AT CLONED
HUMAN SH2 DOMAINS (Ki) CompoundSrc Lck Fyn SH- p85Grb2 Hcp 7 uM X NI NI NI NI X

3 6 uM 11 uM NI NI NI NI X
4 40 uM163 uM NI XX NI NI X
28 uM149 uM NI NI NI NI X
6 13 uM 50 uM NI NI NI NI X
7 20 uM320 uM NI Nl NI NI X
8 12 uM360 uM NI NI NI 330 X
9 55 uM146 uM NI NI NI NI X
XX XX NI NI NI NI X

NI-No inhibition observed below 1000 uM
X-not calculated XX-not tested s While the ~lcfel~cd embo-lim~nt~ of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: ~UN - NlN~'l'ON, DAMIEN

(ii) TITLE OF THE lNv~llON: USE OF LCK SH2 SPECIFIC

(iii) NUMBER OF SEQUENCES: 26 (iv) CORRESPO~ ~ ADDRESS:
(A) ADDRESSEE: SmithKline Beecham Corporation (B) STREET: 709 Swe~el~n~ Road (C) CITY: King o~ Prussia (D) STATE: PA
(E) COUNTRY: USA
(F) ZIP: 19406 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 1.5 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DAT~:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/386,381 (B) FILING DATE: 10-FEB-1995 CA 022l264~ l997-08-08 W 096l24343 PCT/US96/01964 (A) APPLICATION NU~BER: 08/400,220 (B) FILING DATE: 07-MAR-1995 (A) APPLICATION NUMBER: 08/497,357 (B) FILING DATE: 30-Jun-1995 (viii) A~ OKN~Y/AGENT INFORMATION:
(A) NAME: Dustman, Wayne J
(B) REGISTRATION NUMBER: 33,870 (C) REFERENCE/DOCKET NUMBER: P50323-2L1 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 610-270-5023 (B) TELEFAX:
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

( i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Lys Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg CA 0221264~ 1997-08-08 W 096l24343 PCTrUS96/01964 (2) INFORMATION FCR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 0 (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

His His His His His His l 5 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 amino acids (B) TYPE: amino acid (c) sTRANn~nNF~s: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gly Ile Leu CA 0221264~ 1997-08-08 W 096l24343 PCTrUS96/01964 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (8) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp Asp Asp Asp Lys l 5 (2) INFORMATION FOR SEQ ID NO:5:

(i) ~QU~N~ CHARACTERISTICS:
(A) LENGTH: 130 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Lys Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg His His His His CA 022l264~ l997-08-08 W 096/24343 PCT~US96/01964 His His Gly Ile Leu Asp Asp Asp Asp Lys Ala Glu Glu Trp Tyr Phe Gly Lys Ile Thr Arg Arg Glu Ser Glu Arg Leu Leu Leu Asn Ala Glu Asn Pro Arg Gly Thr Phe Leu Val Arg Glu Ser Glu Thr Thr Lys Gly Ala Tyr Cys Leu Ser Val Ser Asp Phe Asp Asn Ala Lys Gly Leu Asn Val Lys His Tyr Lys Ile Arg Lys Leu Asp Ser Gly Gly Phe Tyr Ile Thr Ser Arg Thr Gln Phe Asn Ser Leu Gln Gln Leu Val Ala Tyr Tyr Ser Lys His Ala Asp Gly Leu Cys His Arg Leu Thr Thr Val Cys Pro Thr Ser (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 134 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) ~:Qu~:N~: DESCRIPTION: SEQ ID NO:6:

Met Lys Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg His His His His His His Gly Ile Leu Asp Asp Asp Asp Lys Glu Pro Glu Pro Trp Phe CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 Phe Lys Asn Leu Ser Arg Lys Asp Ala Glu Arg Gln Leu Leu Ala Pro Gly Asn Thr His Gly Ser Phe Leu Ile Arg Glu Ser Glu Ser Thr Ala Gly Ser Phe Ser Leu Ser Val Arg Asp Phe Asp Gln Asn Gln Gly Glu Val Val Lys His Tyr Lys Ile Arg Asn Leu Asp Asn Gly Gly Phe Tyr Ile Ser Pro Arg Ile Thr Phe Pro Gly Leu His Glu Leu Val Arg His Tyr Thr Asn Ala Ser Asp Gly Leu Cys Thr Arg Leu Ser Arg Pro Cys Gln Thr Gln Lys Pro Gln (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 133 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Lys Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg His His His His His His Gly Ile Leu Asp Asp Asp Asp Lys Ser Arg Gly Trp Phe His Arg Asp Leu Ser Gly Leu Asp Ala Glu Thr Leu Leu Lys Gly Arg Gly CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 , 40 45 Val His Gly Ser Phe Leu Ala Arg Pro Ser Arg Lys Asn Gln Gly Asp Phe Ser Leu Ser Val Arg Val Gly Asp Gln Val Thr His Ile Arg Ile Gln Asn Ser Gly Asp Phe Tyr Asp Leu Tyr Gly Gly Glu Lys Phe Ala Thr Leu Thr Glu Leu Val Glu Tyr Tyr Thr Gln Gln Gln Gly Val Leu Gln Asp Arg Asp Gly Thr Ile Ile His Leu Lys Tyr Pro Leu Asn Cys Ser Asp Pro Thr Ser (2) INFORMATION FOR SEQ ID NO:8:

i ) ~Q~N~ CHARACTERISTICS:
(A) LENGTH: 224 amino acids (B) TYPE: amino acid (c) STR~NnFl~NF.. SS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
( iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys CA 022l264~ l997-08-08 55= 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 20 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg (2) INFORMATION FOR SEQ ID NO:9:

( i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 225 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi ) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CA 022l264~ l997-08-08 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 10 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 20 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 2~ 180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Ile Glu Gly 30 Arg (2) INFORMATION FOR SEQ ID NO:10:
r (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 117 amino acids (B) TYPE: amino acid CA 022l264~ l997-08-08 W 096l24343 PCT~US96/01964 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser Ile Gln Ala Glu Glu Trp Tyr Phe Gly Lys Leu Gly Arg Lys Asp Ala Glu Arg Gln Leu Leu Ser Phe Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg Glu Ser Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp Asp Met Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu Asp Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu Gln Gln Leu Val Gln His Tyr Ser Glu Arg Glu Arg Ala Ala Gly Leu Cys Cys Arg Leu Val Val Pro Cys His Lys Gly Met Pro Arg Leu Thr Asn Ser Ser (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 123 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide CA 022l264~ l997-08-08 W 096l24343 PCTAUS96/01964 (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:11:

Gly Met Asn Asn Asn Met Ser Leu Gln Asn Ala Glu Trp Tyr Trp Gly Asp Ile Ser Arg Glu Glu Val Asn Glu Lys Leu Arg Asp Thr Ala Asp Gly Thr Phe Leu Val Arg Asp Ala Ser Thr Lys Met His Gly Asp Tyr Thr Leu Thr Leu Arg Lys Gly Gly Asn Asn Lys Leu Ile Lys Ile Phe His Arg Asp Gly Lys Tyr Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser Val Val Glu Leu Ile Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr 20 Asn Pro Lys Leu Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln Gln Asp Gln Val Val Lys Glu Asp Asn Ser Ser ( 2) INFORMATION FOR SEQ ID NO:12:

(i) ~OU~N~ CHARACTERISTICS:
(A) LENGTH: 112 amino acids (B) TYPE: amino acid (c) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
( iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Thr Ser Arg Arg Trp Phe His Pro Asn Ile Thr Gly Val Glu Ala 5 1 5 . 10 15 Glu Asn Leu Leu Leu Thr Arg Gly Val Asp Gly Ser Phe Leu Ala Arg Pro Ser Lys Ser Asn Pro Gly Asp Phe Thr Leu Ser Val Arg Arg Asn 0 Gly Ala Val Thr His Ile Lys Ile Gln Asn Thr Gly Asp Tyr Tyr Asp Leu Tyr Gly Gly Glu Lys Phe Ala Thr Leu Ala Glu Leu Val Gln Tyr Tyr Met Glu His His Gly Gln Leu Lys Glu Lys Asn Gly Asp Val Ile Glu Leu Lys Tyr Pro Leu Asn Cys Ala Asp Gln Phe Ile Val Thr Asp (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single ( D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(A) NAME/KEY: Other ( B) LOCATION: 4.. 4 (D) OTHER INFORMATION: phosphorylated tyrosine residue CA 022l264~ l997-08-08 W 096l24343 PCTrUS96/01964 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Glu Pro Gln Tyr Glu Glu Ile Pro Ile Tyr Leu (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids (B~ TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(A) NAME/KEY: Other (B) LOCATION: 4.. 4 (D) OTHER INFORMATION: phosphorylated tyrosine residue (xi) ~Q~ DESCRIPTION: SEQ ID NO:14:

Asp Gly Gly Tyr Met Asp Met Ser Lys Asp Glu (2) INFORMATION FOR SEQ ID NO:15:
--CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/0l96 (i) ~QU~ CHARACTERISTICS:
(A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
0 (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(A) NAME/KEY: Other (B) LOCATION: 6.. 6 (D) OTHER INFORMATION: phosphorylated tyrosine residue (xi) ~:Qu~N~_~ DESCRIPTION: SEQ ID NO:15:

20 Glu Asn Gly Leu Asn Tyr Ile Asp Leu Asp Leu (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) sTR~NnFnN~s single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal ~ . , .

CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(A) NAME/KEY: Other (B) LOCATION: 7.. 7 (D) OTHER INFORMATION: phosphorylated tyrosine residue (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Thr Pro Pro His Leu Lys Tyr Phe Tyr Phe Val Val Ser Asp Ser Gly (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 87 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTCCATATGA AAAGTATTCG TATTCAGCGT GGCCCGGGCC GTCACCACCA CCACCACCAC
GGGATCCCCG CTGAAGAGTG GTACTTT

(2) INFORMATION FOR SEQ ID NO:18:

CA 022l264~ l997-08-08 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
0 (iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
GGAATTCTAG ATTACTAGGA CGTGGGGCAG ACGTT

(2) INFORMATION FOR SEQ ID NO:l9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
( v ) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGGGATCCTG GACGACGACG ACAAAGCTGA GGAGTGGTAT TTT

CA 022l264~ l997-08-08 W 096/24343 PCTrUS96/01964 (2) INFORMATION EOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
0 (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) ~Qu~ DESCRIPTION: SEQ ID NO:20:

GGAATTCTAG ACTATTAGGA CGTGGGGCAC ACGGT

( 2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (c) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
CGGGATCCTG GACGACGACG ACAAAGAGCC CGAACCCTGG TTCTT

CA 0221264~ 1997-08-08 (2) INFORMATION FOR SEQ ID NO:22:

(i) ~Ou~:N~ CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:22:

GCTCTAGACT ATTACTGGGG ~ GGGTC TG

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CA 0221264~ 1997-08-08 W 096l24343 PCT~US96/01964 GAAGATCTTG GACGACGACG ACAAATCCCG TGGGTGGTTT CAC

(2) INFORMATION FOR SEQ ID NO:24:
S
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
( v ) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GCTCTAGACT ATTAACTAGT GGGATCGGAG CA

(2) INFORMATION FOR SEQ ID NO:25:

( i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 106 amino acids (B) TYPE: amino acid (C) sTR~NnF~NF~s: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CA 0221264~ 1997-08-08 W 096/24343 PCTrUS96/01964 His Pro Trp Phe Phe Gly Lys Ile Pro Arg Ala Lys Ala Glu Glu Met l 5 l0 l5 Leu Ser Lys Gln Arg His Asp Gly Ala Phe Leu Ile Arg Glu Ser Glu Ser Ala Pro Gly Asp Phe Ser Leu Ser Val Lys Phe Gly Asn Asp Val Gln His Phe Lys Val Leu Arg Asp Gly Ala Gly Lys Tyr Phe Leu Trp Val Val Lys Phe Asn Ser Leu Asn Glu Leu Val Asp Tyr His Arg Ser Thr Ser Val Ser Arg Asn Gln Gln Ile Phe Leu Arg Asp Ile Glu Gln Val Pro Gln Gln Pro Thr Ile His Arg Asp l00 105 (2) INFORMATION FOR SEQ ID NO:26:

~ Qu~ CHARACTERISTICS:
(A) LENGTH: ll amino acids (B) TYPE: amino acid (C) STR~ Nn~nNF..~ single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:
(ix) FEATURE:

(A) NAME/KEY: Other (B) LOCATION: 6...6 (D) OTHER INFORMATION: phosphorylated tyrosine r esidue (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

WO 96l24343 PCTIUS96/01964 Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val

Claims (24)

What is claimed is:
1. A method of treating autoimmune diseases in a subject which comprises administering to the subject a therapeutically effective amount of a compound which:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
2. The method of claim 1 which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
3. The method of claim 1 which comprises administering to the subject a therapeutically effective amount of a compound which:

a. binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
4. The method of claim 3 which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain anda human fyn SH2 domain.
5. A method of inhibiting allograft rejection in a subject which comprises administering to the subject an allograft rejection inhibiting amount of a compound which:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;

c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.
6. The method of claim 5 which comprises administering to the subject an allograft rejection inhibiting amount of a compound which binds to a human lck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
7. The method of claim 5 which comprises administering to the subject an allograft rejection inhibiting amount of a compound which:
a. binds to a human lck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
8. The method of claim 7 which comprises administering to the subject an allograft rejection inhibiting amount of a compound which binds to a human 1ck SH2 domain with a binding affinity greater than one hundred-fold higher than thebinding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
9. A method of inducing immunosuppression in a subject which comprises administering to the subject an immunosuppression inducing amount of acompound which:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
e. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
10. The method of claim 9 which comprises administering to the subject an immunosuppression inducing amount of a compound which binds to a human lck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
11. The method of claim 9 which comprises administering to the subject an immunosuppression inducing amount of a compound which:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
12. The method of claim 11 which comprises administering to the subject an immunosuppression inducing amount of a compound which binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higherthan the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
13. Use of a compound which:

a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; in the manufacture of a medicament for use in treating autoimmune diseases.
14. A use according to claim 13 wherein the compound binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain anda human fyn SH2 domain.
15. A use according to claim 13 wherein the compound:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;

c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
16. A use according to claim 15 wherein the compound binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
17. Use of a compound which:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; in the manufacture of a medicament for use in inhibiting allograft rejection.
18. A use according to claim 17 wherein the compound binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain anda human fyn SH2 domain.
19. A use according to claim 18 wherein the compound:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain.
20. A use according to claim 19 wherein the compound binds to a human 1ck SH2 domain with a binding affinity greater than one hundred-fold higher thanthe binding affinity with which the compound binds to a human src SH2 domain anda human fyn SH2 domain.
21. Use of a compound which:

a. binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compoundbinds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain; in the manufacture of a medicament for use in inducing immunosuppression.
22. A use according to claim 21 wherein the compound binds to a human 1ck SH2 domain with a binding affinity which is greater than fifty-fold higher than the binding affinity with which the compound binds to a human src SH2 domain anda human fyn SH2 domain.
23. A use according to claim 21 wherein the compound:
a. binds to a human 1ck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain;
b. binds to a human hcp SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such 1ck SH2 domain;

c. binds to a human SH-PTP2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain;
d. binds to a human p85 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain; and e. binds to a human Grb2 SH2 domain with a binding affinity which is greater than one hundred-fold lower than the binding affinity with which the compound binds to such lck SH2 domain.
24. A use according to claim 23 wherein the compound binds to a human lck SH2 domain with a binding affinity which is greater than one hundred-fold higher than the binding affinity with which the compound binds to a human src SH2 domain and a human fyn SH2 domain.
CA002212645A 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection Abandoned CA2212645A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US08/386,381 1995-02-10
US40022095A 1995-03-07 1995-03-07
US08/400,220 1995-03-07
US49735795A 1995-06-30 1995-06-30
US08/497,357 1996-02-08

Publications (1)

Publication Number Publication Date
CA2212645A1 true CA2212645A1 (en) 1996-08-15

Family

ID=27409758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002212645A Abandoned CA2212645A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Country Status (10)

Country Link
EP (2) EP0809490A4 (en)
JP (2) JPH10513474A (en)
KR (1) KR19980702115A (en)
AU (1) AU4923796A (en)
BR (1) BR9607614A (en)
CA (1) CA2212645A1 (en)
FI (1) FI973259A (en)
HU (1) HUP9802078A3 (en)
NO (1) NO973659L (en)
WO (1) WO1996024343A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Also Published As

Publication number Publication date
HUP9802078A3 (en) 1999-04-28
NO973659L (en) 1997-10-08
FI973259A (en) 1997-10-08
FI973259A0 (en) 1997-08-07
HUP9802078A2 (en) 1998-12-28
JPH10513474A (en) 1998-12-22
EP0809490A4 (en) 1999-10-20
EP0809490A1 (en) 1997-12-03
BR9607614A (en) 1998-06-09
JPH10513564A (en) 1998-12-22
EP0811159A1 (en) 1997-12-10
WO1996024343A1 (en) 1996-08-15
AU4923796A (en) 1996-08-27
KR19980702115A (en) 1998-07-15
NO973659D0 (en) 1997-08-08

Similar Documents

Publication Publication Date Title
AU2008271116B2 (en) Antiviral compounds
US8809267B2 (en) Antiviral compounds
US8476225B2 (en) Antiviral compounds
US20090047252A1 (en) Antiviral compounds
CA2169136A1 (en) Use of src sh2 specific compounds to treat a bone resorption disease
WO1997002023A1 (en) USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS
US20110082158A1 (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
EP0835104A1 (en) Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
CA2169132A1 (en) Use of hcp sh2 specific compounds to enhance erythropoiesis
CA2212645A1 (en) Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
US20030096760A1 (en) Method of antagonizing the human SRC SH2 domain
WO1998040093A1 (en) Method of antagonizing the human src sh2 domain

Legal Events

Date Code Title Description
FZDE Discontinued